Immunological and hemostatic responses to ventricular assist device support by Woolley, Joshua
 IMMUNOLOGICAL AND HEMOSTATIC RESPONSES  
TO VENTRICULAR ASSIST DEVICE SUPPORT 
 
 
 
 
 
 
 
 
by 
Joshua Ryan Woolley 
B.S. Mechanical Engineering, Geneva College, 2003 
 
 
 
 
 
 
 
 
 
Submitted to the Graduate Faculty of 
Swanson School of Engineering in partial fulfillment  
of the requirements for the degree of 
Doctor of Philosophy 
 
 
 
 
 
 
 
 
 
University of Pittsburgh 
2014 
 
UNIVERSITY OF PITTSBURGH 
SWANSON SCHOOL OF ENGINEERING 
 
 
This dissertation was presented 
by 
Joshua Ryan Woolley 
 
 
It was defended on 
March 20, 2014 
and approved by 
James Antaki, PhD  
Professor, Departments of Biomedical Engineering and Computer Science, Carnegie Mellon University; 
Professor, Departments of Bioengineering and Surgery, University of Pittsburgh 
Harvey Borovetz, PhD 
Robert L. Hardesty Professor, Department of Surgery; Professor, Departments of Bioengineering and 
Chemical and Petroleum Engineering, University of Pittsburgh 
Robert Kormos, MD, FRCS(C), FACS, FAHA 
Professor, Department of Cardiothoracic Surgery, University of Pittsburgh; Director, Artificial Heart 
Program, and Co-Director, Heart Transplantation, UPMC 
Peter Wearden, MD, PhD 
Surgical Director, Pediatric Heart and Lung Transplantation, and Director, Pediatric Mechanical 
Cardiopulmonary Support Program, Children’s Hospital of Pittsburgh; Assistant Professor, Department of 
Cardiothoracic Surgery, University of Pittsburgh 
 Dissertation Director: William Wagner, PhD,  
Professor, Departments of Surgery, Bioengineering and Chemical Engineering, and Director, McGowan 
Institute for Regenerative Medicine, University of Pittsburgh 
 
 
 ii 
Copyright © by Joshua Ryan Woolley 
2014 
 iii 
 Ventricular assist devices (VADs) are critical in the treatment of advanced heart failure, but 
continue to be plagued by infection, bleeding and thrombosis. Immunity may be affected by 
VADs, though most paradigms were developed in older-generation pumps and may not currently 
be applicable. Similarly, hemostasis and platelets may be impacted by device type, though the 
patient’s health may also influence outcomes. Temporal immune cell activation and thrombosis 
biomarkers levels were evaluated across several contemporary pumps. This relationship was 
further studied in vitro through development of a method for visualizing cellular deposition onto 
opaque materials. An improved understanding of the cellular effects of VADs was sought 
through a comparative evaluation of these pumps, and this understanding may aid in the 
development of predictive indices of adverse events and influence future device design. 
Patients implanted with a currently-utilized VAD did not experience changes to adaptive 
immunity reported with previous-generation devices. However, infection was still an ongoing 
risk for these patients. Further investigation found the impact of VADs on immunity was greater 
than that of similar surgeries, especially among innate immunity. Granulocyte activation was 
elevated following VAD implantation, and was significantly pronounced in one model, 
suggesting an influence of design on immune cells. Granulocyte activation promotes 
extravasation and apoptosis, suggesting a pathway for decreased cellular immunity. 
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 iv 
Pre-operative hepatic dysfunction had immediate and long lasting hemostatic effects on 
VAD patients. Model for End-stage Liver Disease (MELD) score was found to be a positive pre-
operative predictor of post-implant bleeding, blood product consumption and elevation of 
thrombosis biomarkers. MELD score was also found to be a stronger predictor of immediate 
post-operative bleeding than device type, underscoring the importance of patient pre-operative 
health on post-operative outcomes. 
With this difficult hemostatic environment, improvement of the blood-contacting surfaces 
of rotary VADs may reduce complications. A flow chamber for real-time visualization of platelet 
deposition onto surfaces of opaque VAD materials under physiologically-relevant conditions was 
developed. This was accomplished through the novel combination of fluorescently-marked 
platelet-rich-plasma and translucent hemoglobin-depleted red blood cells. This method enables 
the hemocompatibility assessment of a wide range of implantable materials. 
 v 
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1.0  INTRODUCTION 
1.1 SIGNIFICANCE 
(Note: A majority of this chapter was previously published as: Woolley JR, Kormos RL, Wagner 
WR. Biologic responses to the interface between device and circulation. In:Kormos RL, Miller 
LW, editors. Mechanical circulatory support: a companion to Braunwald’s heart disease. 
Philadelphia: Elsevier; 2012. p. 249-257.) 
Left Ventricular Assist devices (VADs) present a unique challenge for blood biocompatibility 
from other medical devices in that blood contacts a large surface area with complex flow fields 
for an extended period of time. Other chronic devices such as stents or grafts may have surface 
areas that are orders of magnitude smaller with favorable flow conditions, while similar-sized 
devices, such as membrane oxygenators, are intended for acute use in the presence of substantial 
anticoagulation. In contrast, a VAD patient’s blood must come in extensive contact with artificial 
surfaces for months or years while simultaneously being weaned to the lowest allowable levels 
of anticoagulation preferable for chronic use. In light of these challenging circumstances, it is not 
surprising that many of the biological complications such as thrombosis, thromboembolism and 
bleeding encountered with the first implants with this technology are still problematic today. 
These complications contributed to a dampening of the initial enthusiasm for application of these 
devices to heart failure patients, and remain problematic for clinicians and device designers.[1,2] 
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The first VADs mimicked the biphasic flow of the natural heart and served as effective 
bridges to transplant for heart failure patients waiting for donor organs.[3] The volume 
displacement required for pulsatile flow made these VADs large in size, preventing implant in 
smaller patients. The introduction of rotary blood pumps decreased the size and power 
requirements and increased the mechanical life of VADs, expanding the size of eligible patient 
population and increasing their overall quality of life.[4] The use of sophisticated computational 
fluid dynamic modeling programs and the utilization of magnetic levitation to eliminate bearings 
improved the blood path through the pumps, helping to improve hemocompatibility. However, 
even with these technological advancements, all VAD patients are still vulnerable to hemostasis 
problems such as thrombosis, thromboemboli, and bleeding.[5,6] 
1.2 SURVEY OF THROMBOSIS AND BLEEDING COMPLICATIONS IN THE 
SETTING OF VENTRICULAR ASSIST DEVICES 
Thromboembolic rates in VAD patients can be difficult to define and compare, with reported 
rates varying substantially between specific VADs and institutions. Early reports and 
investigational device studies may have different levels of reporting that could distort cross-
comparisons. For example, Goldstein et al combined “embolic stroke, transient ischemic attack, 
and peripheral embolism” into one parameter of “thromboembolic event”[7]; in contrast, Miller 
et al report separately on ischemic stroke, hemorrhagic stroke, transient ischemic attack, “other 
neurologic” and “peripheral nonneurologic thromboembolic event”.[4] The combination of 
careful assessment of potential thromboembolic events together with standardization of these 
methods and reporting across centers was needed to provide a better framework for comparative 
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studies between devices and patient management protocols. A related situation was found in the 
reporting of bleeding rates.[4,8]  
Given this need, the Interagency Registry for Mechanically Assisted Circulatory Support 
(INTERMACS©), a voluntary national patient registry for FDA-approved devices, was formed 
as a centralized source for various VAD implant information including detailed adverse event 
definitions and rates. INTERMACS also provides standardized definitions for suspected 
neurological or bleeding events.[9] (Figure 1.1) In addition to reporting each adverse event, 
institutions participating in INTERMACS must provide information on aspects surrounding the 
event, such as date and location of patient during onset, contributing factors, event type and 
severity, anticoagulation therapy, and mortality, among other details.[9] Based on these 
definitions, INTERMACS investigators reported in 2008 that 18% of VAD patients experience 
neurologic dysfunction and 35% have bleeding complications (420 patients).[10] An update of 
this report reveals actuarial freedom from stroke to be 89%, 83% and 81% for implant years 1, 2 
and 3 respectively (N=5366; continuous flow VADs only). When the rate of neurologic 
dysfunction was separated by pulsatile and continuous flow devices, pulsatile LVAD patients 
experienced a significantly higher adverse event rate of 3.81 compared to continuous flow 
patients at 1.83 (events/100 patient-months in the first 12 months of implantation; pulsatile 
LVAD N = 594, continuous flow LVAD N = 5358). The same comparison of patients found 
bleeding adverse event rates were higher in pulsatile LVAD patients than continuous flow 
LVADs (17.28 v 9.45, respectively).[6] Additionally, biventricular support presents an especially 
challenging situation as twice the artificial surface is implanted into typically the sickest of VAD 
patients. INTERMACS reported in 2009 substantially higher bleeding rates for pulsatile 
biventricular support compared to only LVAD support (55% vs. 35%); interestingly, neurologic 
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complications are slightly lower for biventricular support (16% vs. 18%), illustrating the 
challenge clinicians face in attempting to predict risk factors for adverse events (465 LVADs, 
128 BiVADs).[11] Recent data reveals that actuarial freedom from infection, bleeding event, 
stroke, device malfunction or death to be much lower in BiVAD patients compared to continuous 
flow LVADs (14 vs 30% respectively at 12 months of support; BiVAD N = 145, LVAD N = 
5291).[6] 
 
Figure 1.1: INTERMACS definitions for Major Bleeding and Neurological Dysfunction. Note: hemorrhagic 
stroke is considered a neurological event and not a separate bleeding event. From INTERMACS Manual of 
Operations, version 3.0.[9] 
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Outside of INTERMACS, other researchers and institutions have reported bleeding and 
thrombotic adverse event rates in the literature. Given the different flow fields and shear stresses 
in each type of pump, one would expect that pulsatile and rotary pumps may have different rates 
of adverse events. The Thoratec pulsatile internal pneumatic VAD (IVAD) was reported to have 
stroke rate of 8% and bleeding rate of 46% (33% requiring re-operation)(39 patients in the 
study).[12] Miller et al reported on the HeartMate II rotary VAD bridge to transplantation (BTT) 
trial in which 11% of patients experienced hemorrhagic or ischemic strokes (0.18 events/patient 
year), 2% pump thrombosis and 41% of patients had bleeding requiring re-operation (a slight 
increase in thromboembolic complications over the pulsatile Thoratec IVAD) (133 patients).[4] 
An update on this report by Pagani et al through the BTT trial’s continued access protocol 
revealed that 53% of HeartMate II patients experienced a bleeding event, with 26% requiring re-
operation (1.67 and 0.45 events/patient year, repectively).[13] Embolic stroke afflicted 5% of the 
patients (0.09 events/patient year) and another 1% had primary device thrombosis requiring 
surgical intervention (0.04 events/patient year; 281 patients). Starling et al reported on the 
HeartMate II BTT post-approval trial in which 44% of HeartMate II patients experienced a 
bleeding event (1.44 events/patient year) and 4.7% experience an embolic stroke event (0.06 
events/patient year; 169 patients).[14] In destination therapy (DT) patients, Slaughter et al 
reported on 81% of HeartMate II patients that experienced a bleeding event (1.66 events/patient 
year) with another 30% requiring reoperation for bleeding (0.23 events/patient year).[15] Similar 
to the BTT trials, Slaughter et al reported that 8% DT patients experienced thromboembolic 
stroke and another 4% had pump thrombosis (0.06 and 0.02 events/patient year, respectively; 
134 patients). Furthermore, in an illustration of differences between implant centers, John et al 
reported on the HeartMate II but in a single-center setting; of these patients, only 3% 
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experienced stroke and 15% had bleeding that required re-operation (a significant reduction in 
adverse event rates compared to previous reports) (47 patients).[16]  
Recently, a report from Starling et al discussed a troubling and sudden increase in pump 
thrombosis across three major HeartMate II implant centers.[17] The Cleveland Clinic, 
Washington University Barnes-Jewish Hospital, and Duke University combined to form a single 
report on patients implanted with the HeartMate II from 2004 to 2012. The report found that 
prior to 2011 only 2.2% of patients experienced pump thrombosis within 3 months of support, 
while 8.4% of patients implanted from 2011 to 2013 had pump thrombosis, a four-fold increase 
(837 patients). (Figure 1.2) Of those patients that were not able to be transplanted and 
experienced pump thrombosis, mortality was 48.2%. Although the authors could not identify a 
single cause for this observed increase, the authors suggested that modifications to the outflow 
graft and bend relief as well as modifications to the inflow conduit, perturbations that affected 
flow around the bearing, and changes to the anticoagulation regimen may have been contributing 
factors, Additionally, the authors noted that any perturbations that affected flow around the 
blood-lubricated bearing (such as aortic regurgitation, cannula kinking, and arrhythmias) could 
have decreased heat dissipation and increased protein deposition around the bearing. 
Interestingly, the target INR recommendation during this period was reduced due to an increase 
in bleeding complications from acquired Type 2 von Willebrand Syndrome that has been 
associated with implantation of this pump.[18] However, the authors were not able to prove 
correlation of thrombosis with these changes.  
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 Figure 1.2: Increase in confirmed HeartMate II pump thrombosis at three active implanting institutions after 
March 2011. This trend was surprising and unexpected by the authors as all three institutions had been 
regularly implanting HeartMate II LVADs since 2004. From Starling et al. [17] 
 
The introduction of impeller-levitation technology (no internal bearings; single moving 
part) and improved fluid dynamics design on VADs have not been able to eliminate these 
complications. One such pump (Ventracor LVAD) reported stroke in 24% of patients (0.48 
events/patient year), 15% thrombosis and/or thromboembolism, and 24% hemorrhage (0.48 
events/patient year) (33 patients).[19] The European clinical trial for the HeartWare HVAD 
reported bleeding events in 24% of patients and ischemic stroke in 4% (0.27 and 0.04 
events/patient year, respectively; 50 patients).[20] The US clinical trial for the HeartWare 
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HVAD exhibited slightly different event rates, with 15% of patients experiencing bleeding that 
necessitated reoperation and 7.5% experiencing embolic stroke with another 4% needing pump 
exchange due to thrombus formation (0.19, 0.09 and 0.05 events/patient year, respectively; 332 
patients).[21] (Figure 1.3) A single-center report on HeartWare patients by Wu et al revealed 
bleeding events in 23% of patients, with 84% of the events requiring reoperation.[22] Wu et al 
also reported 7% of the patients died due to a central nervous system event, with another 1% of 
patients requiring pump exchange for pump thrombosis (141 patients). A similar single-center 
report revealed that 26% of patients implanted with the HeartWare HVAD had an ischemic 
stroke (50 patients).[23] 
 
Figure 1.3: Device thrombosis in the inflow cannula of a continuous flow ventricular assist device. From 
Eckman et al. [24] 
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As clinicians become more familiar with these patients and devices, improvements in 
event rates due to progress in patient anticoagulant management have also been reported in the 
literature. Long et al demonstrated decreases in adverse event rates through refined patient 
management and pre-implant screening; a new patient management protocol provided by the 
manufacturer addressed patient selection, wound care, nutrition and perioperative and 
postoperative care. Long continued to show that for patients implanted with the pulsatile 
HeartMate XVE, neurologic dysfunction (0.15 vs. 0.39 events/patient year) and bleeding (0.15 
vs. 0.46 events/patient year) were reduced under the new protocol when compared to previously 
published values that were collected during early use of this device (42 patients).[8,25] Similarly, 
the HeartWare HVAD BTT trial revealed an improvement in ischemic cerebrovascular accident 
rates following a change to the anticoagulation protocol during the study (0.11 events/patient 
year, N = 253 v 0.07 events/patient year, N = 211).[21] 
These relatively high complication rates remain troubling for clinicians, especially when 
compared to similar heart failure populations that do not receive VAD support but remain on 
optimal medical therapy (OMT). Rogers et al followed OMT patients for a comparable length of 
time as VAD implantation and found that 11% experience stroke while 0% experienced bleeding 
(18 patients).[26] Similarly, Rose et al found neurological dysfunction at a rate of 0.09 
events/patient year and no bleeding events (61 patients).[8] A meta-analysis by Witt et al found 
that only 5% of heart failure patients experience ischemic stroke within the first 5 years of 
diagnosis.[27] 
 Regardless of the pump or institution, studies suggest that patients are most at risk 
for thromboembolism and bleeding events during the first 30 days of VAD 
implantation.[4,7,8,17,28,29] (Figure 1.4) Refinement of anticoagulation protocols and 
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increased experience with this patient population has helped to reduce the quantity and severity 
of these events, but they are still high enough to give pause to referring clinicians on the 
effectiveness of this technology. Additionally, thromboembolic events causing neurological 
damage are frequently seen as especially pernicious complications due to their often sudden 
onset and debilitating nature. Previous INTERMACS data shows that neurologic adverse events 
are the primary cause in 18% of deaths while on device, while surgical bleeding accounts for 
only 3%.[10] Clearly more investigation into changes in the hemostatic state of these unique 
patients post-implantation is warranted, and may enable clinicians to advance the management of 
this population and improve outcomes of morbidity and mortality.[30,31] 
 
Figure 1.4: Neurological, bleeding and infection adverse events from a report on the Mechanical Circulatory 
Device Database. Notice the preponderance of thromboembolism and bleeding incidents in the first 30 days of 
support, as well as the continued risk for infection throughout the implant period. From Deng et al. [29] 
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1.3 VIRCHOW’S TRIAD APPLIED TO VENTRICULAR ASSIST DEVICES 
Thrombogenicity is a material characteristic that may be used interchangeably to describe the 
localized formation of blood clots, the systemic damage inflicted by embolization of a clot, or 
the destruction or consumption of blood components resulting in a relative reduction in the 
ability of blood to function normally.[32] Each of these facets of thrombogenicity may contribute 
to the failure of a medical device to function properly with the host. A device may trigger a 
“stabilized” local thrombus formation that is well-anchored to the substrate; however, it is 
difficult to accurately predict the location and size of adherent thrombus and an ill-placed clot 
may completely undermine the function of the device (e.g. incomplete valve seal; stent 
occlusion). Additionally, a material may resist thrombus adherence but still cause embolism 
through transient clot formation; hence, there are reports of in vivo material evaluations 
demonstrating “clean” surfaces but producing end-organ infarcts.[33] Furthermore, some devices 
exhibit a continual destruction or removal of blood cells or proteins resulting in a hemostatic 
imbalance that may contribute to adverse events (e.g. consumptive coagulopathy from 
oxygenator circuits; anemia from hemolysis). Often times a device will present a combination of 
these problems, confounding attempts to improve the device or even to properly isolate the 
offending processes. Notice though that a thrombogenic device may cause seemingly opposite 
adverse events within the same host; namely, unregulated clot formation and uncontrolled 
bleeding. 
 In a healthy individual free from implant, a balance is maintained between the 
coagulation and fibrinolytic systems to prevent severe blood loss during vessel puncture while 
also re-establishing normal blood flow to the vessel following repair.[34] In 1856 Rudolph 
Virchow proposed that the interaction of the constitution of the blood, interrupted blood flow, 
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and irritation of the blood vessel contributed to the phenomena of venous thrombosis (Virchow’s 
Triad).[35] His insight helped to qualitatively describe the underlying processes responsible for 
thrombus formation and helped to isolate key variables that could be optimized by researchers to 
minimize thrombogenicity in medical procedures. However, when artificial surfaces are 
introduced, this balance may be disrupted by the body’s interaction with the foreign matter 
resulting in unregulated reactions that may be difficult to remedy.[36-39] Virchow’s Triad still 
provides the framework for medical device design and assessment, with an expansion on the 
composition of the blood and subtle changes to the other variables to reflect a more general 
application to artificial and organic surfaces. Blood coagulation in the setting of artificial 
surfaces involves three areas of interdependency: the blood (platelets, the coagulation cascade, 
fibrinolysis), the flow over the material, and the blood-contacting material.[34] Below is a brief 
discussion of each variable as it relates to VAD thrombosis and hemostasis. 
 
1.3.1 Blood: the delicate balance   
When first contacted with blood, artificial surfaces very quickly undergo protein adsorption, 
forming a layer over the material almost instantly. This dynamic protein layer is 
thermodynamically driven by the Vroman effect, where smaller, diffusible proteins initially 
adsorb to the material surface and are gradually displaced by less diffusible proteins with higher 
affinity for the surface.[40] All subsequent blood interactions with the device then involve the 
plasma proteins with the most affinity for the material and not the material surface itself. The 
shear forces of the flowing blood on the surface will further influence the Vroman effect; a high 
shear stress setting (e.g. arterial flow) may remove all low-affinity proteins that may be present 
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on the same material in a low shear milieu (e.g. venous flow; recirculation zones). This adds 
substantial complexity to predicting device thrombogenicity since the same material may have 
different adsorbed proteins depending on the flow through the device.[36] 
Platelets adhere to artificial surfaces through the binding of platelet surface receptors with 
adsorbed plasma proteins; in particular, glycoprotein Ib (GP Ib) adheres to adsorbed von 
Willebrand factor (vWF) while glycoprotein IIb/IIIa (GP IIb/IIIa) adheres to adsorbed 
fibrinogen, fibronectin and vWF.[41,42] This process is driven by the shear force of the blood 
such that at lower wall shear rates (<1000 s-1), binding is dependent on GP IIb/IIIa, while at 
higher shear rates the tethering shifts to GP Ib.[41] Adherent platelets become activated resulting 
in the release of the contents of internal vesicles (α- and dense granules) into the extracellular 
environment, formation of pseudopodia, exposure of phosphatidylserine (a negatively-charged 
phospholipid) and binding with other platelets to form aggregates. Dense granules contain 
platelet activation agonists such as adenosine diphosphate (ADP), calcium ions and serotonin 
that help to recruit passing platelets to the site of injury and solidify the platelet aggregate. The 
phospholipid surface of the deposited platelet mass provides a catalytic surface for the cleavage 
of prothrombin to thrombin; thrombin then is a potent platelet activator and serves as a positive 
feedback agent for the growing thrombus. Additionally, there is a growing body of literature 
suggesting that high shear stress regions may induce low-level activation in the platelet, causing 
the formation of tendrils that then bind to adsorbed proteins or adherent platelets to form 
aggregates.[43]  
 Blood coagulation involves the serial proteolytic cleavage of circulating plasma 
proteins converging in the activation of prothrombin to thrombin. Of particular importance for 
artificial materials is the intrinsic system of the coagulation cascade leading to the common 
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pathway. The negatively charged surface of the deposited platelets provides a favorable 
environment for the anchoring of plasma proteins involved in the initial steps of the intrinsic 
system. The formation of the platelet plug may help to reduce the flow of blood through the area 
of insult, allowing the coagulation proteins to form a local gradient to aid in the rapid 
development of the thrombus. 
 The fibrinolytic system regulates the clot formation through the degradation of 
excess fibrin mesh, allowing flow to return to normal to the region of insult after healing. 
Plasminogen is the principle fibrinolytic agent and is incorporated into the fibrin mesh during 
clot formation. During healing, plasminogen activators are released by cells near the injury (such 
as tissue plasminogen activator and urokinase) and the fibrin mesh is disassembled.[34] 
 Not only are VADs ambitious for the amount of surface area exposed to the blood 
and the length of time implanted, but these devices are reserved for implant into some of the very 
sickest patients. VAD patients often have conditions that predispose them to blood clots (such as 
coagulopathies, fibrillation, ischemia, etc) before VAD placement and the artificial device may 
unfortunately serve to aggravate the issue. Additionally, 44% of patients are implanted following 
critical cardiogenic shock which characteristically magnifies extreme inflammation and 
hypercoagulation.[10] Post-operative patient management is difficult and frequently includes 
administration of blood products and varying levels of anticoagulation. The effects of surgery 
and post-operative care on the blood cells can last for weeks before reaching steady state. In 
short, the hemostatic state VAD patients represent one of the most challenging environments in 
which to place a medical device.  
 As stated previously, post-operative bleeding and adverse neurological events are 
more prevalent during the first month of implantation. Bleeding may be broadly defined by a 
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combination of chest tube drainage, blood products required and re-operation for hemorrhage. A 
number of mechanisms contribute to difficulties in patient management during this early post-
operative period. The highly invasive surgical procedure is associated with blood loss, 
hemodilution, coagulation protein consumption and platelet activation.[44] The dynamic 
hemostatic state of these patients immediately after implant often drives clinicians to delicately 
balance the anticoagulation regimen to ensure proper inhibition of thrombosis while preventing 
over-anticoagulation (and associated bleeding).[45-47]  
Some reports have shown that the traditional measures of anticoagulation such as aPTT 
and INR are not predictive of observed thromboembolic events.[48] Difficulties with keeping a 
patient’s INR in range while on warfarin (and the poor outcomes associated with highly variable 
INR values) have been studied.[49] (Figure 1.5) In an effort to find more descriptive indices of a 
patient’s hemostatic state (and possibly predictors of adverse events), researchers and clinicians 
have investigated circulating biomarkers of thrombosis and fibrinolysis. Joshi et al measured 
INR, aPTT and prothrombin fragment F1.2 (F1.2; a protein cleaved when prothrombin is 
converted to thrombin) in VAD patients daily before discharge, then weekly thereafter. The 
investigators found that an elevation of F1.2 was a significant predictor of neurological events 
while INR and aPTT were not.[48] Additionally, Wilhelm et al found increasing levels of plasma 
F1.2 coincided with an increase in cranial microembolic signals measured using transcranial 
doppler.[50] Global platelet activation has been investigated through measurement of plasma 
levels of proteins released from platelet alpha granules (platelet factor 4 and beta-
thromboglobulin).[51,52] Individual interrogation of platelet activation state has been performed 
by flow cytometry through measurement of surface expression of CD62P and CD63 (both cell 
receptors are found in platelet alpha granules and are expressed upon activation).[50,53] These 
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reports suggest that platelet activation levels in VAD patients rise after implant and continue to 
be elevated through the duration of support. D-dimer has been targeted as a potential indicator of 
thrombus formation as it is a by-product of fibrin degradation.[51,54] Platelet response to 
stimulation[55,56], circulating thrombin-antithrombin III complex[52], plasminogen activator 
inhibitor-1[56], monocyte-platelet aggregates[50], and monocyte expression of tissue factor[57], 
among others, have also been targeted to help assess the patient’s coagulation state as well as 
predict adverse events. 
  
Figure 1.5: (Left) Percentage of INR values outside of the therapeutic range (2-4) for 1272 heart valve 
patients. (Right) Linearized Death Rate for mitral valve replacement patients outside of the therapeutic INR 
range of 2-4 (647 patients). From Butchart et al. [49] 
 
While the hemostatic state of VAD patients is often varied and dynamic, anticoagulation 
protocols are surprisingly uniform across institutions and devices, based upon heparin in the 
perioperative and immediate post-operative period, and chronic warfarin administration 
supplemented with ASA and/or dipyridamole as additional anti-platelet 
agents.[4,12,17,19,26,51,58,59] Advancements in individualized therapy may help to 
significantly reduce the occurrence of adverse events through patient-specific regimens. Platelet 
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genotyping and platelet function testing for detection of hyper- or hypo-responsiveness to 
anticoagulation or anti-platelet agents have been increasingly employed for other cardiac 
procedures (such as stent and valve placements)[60,61]; however, consensus on the utility and 
robustness of this approach has not yet been achieved.[62] Another approach to tailored 
medicine is systems biology modeling of patient-specific blood response to activating factors and 
pharmaceutical agents. Several complex coagulation models are being developed (reviewed by 
Diamond[63]) that allow for user-input of values such as coagulation factor concentrations and 
platelet response to known agonist concentrations. Patient-specific data may be obtained (for 
individualization of the model) by high-throughput blood screening using microfluidics blood 
analysis. The result is a powerful tool that may be able to diagnose blood defects or predict the 
effectiveness of anticoagulant and anti-platelet agents. However, further progress needs to be 
made regarding robustness of the models, computational capabilities and clinical implementation 
before the potential of this technology is realized.[64,65] 
 
1.3.2 Flow: complex flow fields with a non-Newtonian fluid 
As described earlier, blood flow controls the rate of incidence of blood cells and proteins 
contacting the device wall through diffusion and convection.[66] Flow fields and shear stresses 
in VADs vary dramatically between different types of pumps and even in different regions 
within the same pump. The shear forces of the blood help to determine the composition of 
adsorbed proteins and resultant thrombus. Areas of recirculation within a pump may trap 
platelets, increasing their exposure time to the artificial surface while also increasing the local 
concentrations of agonists released from previously adherent platelets. High-shear regions within 
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a pump may become problematic as passing platelets are transiently activated by the shear and 
deposit on pump seams and bearings that under low shear flow may have been clean of 
thrombus. In contrast, areas of uninterrupted laminar flow at moderate shear stresses may 
increase the hemocompatibility of the device by reducing platelet exposure time to artificial 
surfaces and rapidly removing or diluting agonists from previously adherent platelets. Thus the 
flow conditions within the VAD may enhance or exasperate the hemocompatibility of the pump 
surface, undermining even the best attempts at presenting an optimal surface to prevent platelet 
adhesion and activation. 
Shear forces are substantially different between different VAD models depending on a 
myriad of factors, not the least of which includes if the pump is pulsatile or rotary. Pulsatile 
pumps are generally characterized as low-shear flow due to the slow filling of a large blood sac 
and then the gradual increase in pressure to dispel the fluid. However, this is only true when the 
shear stresses are averaged over an entire pump cycle; the biphasic nature of pulsatile pumps 
causes changing conditions that may result in transiently sub-optimal flow conditions at localized 
regions in the pump. For example, shear stresses at the valves during systole will initially be very 
severe (a high-velocity nozzle during the opening of the valve) and then decrease greatly (fully 
open valve becomes a large-diameter tube), even resulting in recirculation and stasis zones near 
the valves once they close during diastole.[67,68] Pulsatile pumps often operate with a “residual 
volume” of blood that is unable to be completely dispelled from the blood sac during diastole 
due to geometric constrains of the pump. This residual volume of blood is inevitably exposed to 
the pump surface for a relatively long time and may become a nidus for platelet deposition or 
bulk phase aggregate formation. Though most pulsatile pumps are designed such that the fluid 
rotationally fills the pump sac (to discourage stasis in the pump during the transition from 
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diastole to systole), this phenomenon is imperfect and unable to completely remove the flow 
disturbances that occur during transitions in biphasic flow conditions.[67] (Figure 1.6) These 
disturbances in flow may dislodge adherent thrombi or break off aggregates sending emboli 
downstream with possibly catastrophic results. 
 
Figure 1.6: Particle image velocimetry of a pulsatile VAD at the onset of pump systole.  Notice the initial high 
velocity at the opening of each valve followed by low velocity caused by recirculation and stasis. From 
Hochareon et al. [68] 
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Rotary VADs are different from pulsatile pumps in that the blood continuously flows 
through the pump at a relatively constant rate. Rotary VADs employ the use of a spinning 
impeller to move the blood forward; depending on the VAD, this impeller may be supported by 
bearings in the flow field or magnetic suspension. The blade tips of the spinning impeller in 
rotary VADs presents regions of consistently high-shear stress that gradually decrease towards 
the center of the flow field. These high-shear regions vary between pumps (often depending on 
the width of the gap between the impeller blades and pump housing, among other factors) but are 
usually supraphysiological.[69] Leverett et al described a relationship between cell exposure 
time and shear stress which helps to define the hemolysis threshold for blood cells (Figure 1.7); 
as such, many researchers attempt to design pump operation within this limit but this is often not 
possible.[70] However, despite continuously exposing blood to high shear regions, these pumps 
have not experienced the hemolysis that was a concern during development.[71] Studies have 
suggested that laminar flow through the pump allows a cell-free boundary layer to form, which 
then experiences most of the high-shear regions while pushing the cells toward the lower shear 
regions, effectively excluding the cells from the high shear stresses. For pumps that require 
bearings, this area has typically required special design to limit stasis at the bearing site and 
reduce blood damage from friction leading to crushing of cells and local heat generation. 
Thrombus forming at the bearings of pumps has been especially problematic as it not only poses 
a biological threat of embolization, but a mechanical threat to the pump due to abnormal bearing 
wear and/or unexpected power consumption (limiting the accuracy of flow estimation and 
reducing battery life). Magnetically levitated impellers are not unaffected by problems though, as 
the slightest thrombus formation on an impeller blade may disrupt the delicate magnetic balance 
and cause the impeller to crash into the pump housing. 
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 Figure 1.7: Original curve from Leverett et al suggesting the shear stress limits to red blood cells before lysis. 
The “safe zone” for red blood cells is beneath the curve. From Leverett et al. [70] 
 
Computational fluid dynamics (CFD) is the mathematical simulation of fluid flow in 
which a programmer is able to import a technical drawing of a VAD and model varying 
conditions of blood flow.[72] CFD has emerged as a powerful tool for designers to visualize the 
effects of pump changes during development and identify potentially problematic flow fields in 
silico.[73] CFD allows for the in silico manipulation of design of the pump in order to optimize 
targeted design parameters and predict pump performance prior to fabrication.[74,75] However, 
the non-Newtonian nature of blood increases the difficulty of predicting flow through even the 
simplest medical devices, while VADs present some of the most complex flow geometries in 
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medicine. Additionally, research is still ongoing concerning which parameters in the pump 
design are most important during optimization.[76] 
 
1.3.3 Material surface: where body and machine interface 
In addition to differing fluid dynamics, pulsatile and rotary VADs usually contain different blood 
contacting surfaces due to the material design requirements specific to each pump. Despite these 
differences the various materials are selected for relative blood biocompatibility, meaning 
relative resistance to thrombotic deposition and a lack of hemolytic activity. The blood sac in 
many pulsatile VADs is composed of a durable elastomer incorporating a manufacturer-specific 
non-thrombogenic molecular component at the surface. For example, the Thoratec pneumatic 
VAD contains an inflow cannula and blood sac composed of a proprietary polymer consisting of 
polyurethane blended with a biocompatible surface modifier (Thoralon) intended to reduce 
thrombogenicity.[77]  
The biocompatibility strategy pursued by the HeartMate XVE VAD is in stark contrast to 
other pulsatile and rotary VADs. Rather than utilizing blood contacting surfaces that do not 
support platelet deposition, the inside of the HeartMate XVE contains on one side a stationary 
titanium wall covered in sintered 50-75 µm titanium microspheres and on the other side a 
pusher-plate covered by a roughly textured Biomer polyurethane diaphragm.[78] These 
thrombogenic surfaces encourage the formation of a highly organized clot that firmly anchors 
and matures into a “pseudointima” composed of platelets, monocytes, lymphocytes, fibroblasts 
and in some cases endothelial cells.[79,80] This biological blood interface has allowed many 
patients to be effectively weaned from all anticoagulant medications except aspirin with few 
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thromboembolic events.[81] While mechanical problems and size considerations have caused 
reductions in patient volume, the challenge to traditional paradigms by the HeartMate XVE will 
continue to be studied by researchers for application in future medical devices. Interestingly, this 
technology has not been successfully translated to rotary VADs, possibly due to the low 
tolerances and clearance requirements that are not compatible with the inability to control the 
thickness of the pseudointima layer. 
The pump housing and impeller found in rotary VADs require hard materials that may be 
easily manufactured and able to withstand mechanical wear. Some manufactures are able to use 
hard polymers (e.g. polycarbonate in the Levitronix Centrimag) or coatings (e.g. diamond – like 
carbon coating (DLC) on the Ventracor Ventrassist[82]) to improve thrombogenicity, but most 
rotary VADs use a highly polished titanium alloy (TiAl6V4) as the blood – contacting material 
(e.g. Thoratec Heartmate II, Jarvik 2000, HeartWare HVAD).[82] TiAl6V4 excels at the material 
properties described above; it also is non-magnetic which allows it to be incorporated into pumps 
that are magnetically suspended and/or controlled.  
TiAl6V4 produces an oxide layer which helps to make this material relatively inert to 
thrombus formation. However, the tolerance of blood to this material appears to be proportional 
to the width of the oxide layer, which may vary in vivo; additionally, titanium without the oxide 
layer is relatively thrombogenic and has exhibited problems with general biocompatibility 
compared to other surfaces.[83] One area of improvement being explored by researchers is the 
development of long-lasting coatings applied to the blood – contacting surfaces within the 
pumps. Synthetic phospholipid polymers have been studied extensively for their ability to mimic 
cell surfaces to prevent platelet activation and adhesion.[84,85] Polymers containing 
phosphorylcholine groups appear to be especially promising for reducing thrombogenicity, in 
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particular the covalent attachment of 2- methacryloyloxyethylphosphorylcholine (MPC) to 
titanium alloys.[86-88] (Figure 1.8) Polyethylene glycol (PEG) coatings have also been 
extensively studied due to the remarkable resistance of PEG to protein adsorption (and hence 
platelet adhesion).[89] However, PEG is typically adsorbed onto the titanium surface resulting in 
a weak coating; the flow rates experienced under normal pump operation may lead to a relatively 
quick removal of the coating, exposing the thrombogenic titanium. Another limiting factor with 
the application of this technology is the prohibitive costs for FDA approval (if necessary) or 
third-party licensing (if patented by other manufacturers). Regardless, the shortcomings and 
uniform use of titanium as the primary blood contacting material in rotary VADs provides an 
opportunity for great strides to be made in reducing thrombotic events through investment in this 
area of research. 
 
Figure 1.8: Reduction of platelet adhesion to a titanium substrate after application of a 
phosphorycholine polymer (MPC) as shown by scanning electron micrographs of the surface following 
contact with sheep blood.  (A) polystyrene positive control. (B) TiAl6V4. (C) TiAl6V4 just prior to attachment 
of MPC (as a control surface). (D) MPC coated titanium. From Ye et al. [88] 
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1.3.4 Thrombosis modeling: application of Virchow’s Triad to predict device 
performance 
Advancements in computing power and mathematical modeling have allowed for recent attempts 
by researchers to develop a tool for predicting thrombus formation in silico during the design of 
medical devices.[90-92] Complex modeling of the interaction between blood constituents, flow 
fields and blood-contacting surfaces involves a concerted balanced effort to advance both the 
accuracy of the numerical simulations and the experimental methods necessary for providing 
input values and validating outcomes.[93] The success of such a tool could greatly reduce the 
cost of developing a VAD while possibly improving the performance of the device. VAD design 
typically consists of a trial and error methodology to reduce the thrombogenicity of the pump; 
often many design generations are produced due to the discovery of unforeseen thrombogenic 
areas revealed with each consecutive round of testing, driving up the cost of the product. Even 
after multiple design iterations and expensive pre-clinical animal testing, clinical trials free of 
thrombotic events are not assured.[94,95] As discussed above, progress in VAD CFD research 
has helped to elucidate some of the nonphysiological flow fields presented in mechanical valves 
and rotating impellers; combined with experimental determinations of protein and platelet 
interactions with given materials, a predictive numerical relationship may be able to be defined 
between the flowing blood and the VAD.[96,97] One form the mathematical model may take is 
that of a map of the probability and location of thrombus formation within the VAD.[90] 
Researchers could then use this information to design out the “hot spots” predicted in the model, 
optimizing the pump in silico for a fraction of the cost of previous design methods.[98] Though 
the accuracy of the current models still needs to be refined, this area of research will be vital to 
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decreasing adverse events and improving outcomes as the future of VAD technology continues 
to evolve. 
1.4 SUMMARY OF INTRODUCTION 
Technological innovation in mechanical circulatory support has greatly improved the lives of 
people afflicted with end-stage heart failure. New devices and advancements in peripheral 
equipment have expanded the eligible patient population, making this therapy now routine in 
some institutions. Despite the mechanical progress, some of the same problems experienced with 
the first implants are still confounding clinicians today. Thrombosis, thromboembolism and 
bleeding remain major complications plaguing VAD patients and are persistent partly because of 
their multi-factorial nature. Tools such as blood biomarkers, individualized anticoagulation 
therapy, CFD, platelet-resistant coatings and thrombosis modeling may help to decrease the 
amount of adverse events experienced with this technology while positioning it at the forefront 
of heart failure support and transplant medicine. 
1.5 OBJECTIVES 
As has been discussed above, VAD support is challenging due to a number of factors including 
the intended duration of support, the health of the population expected to receive the device and 
the surface area of the materials exposed to blood. It is not surprising then that cellular immunity 
of VAD patients has been shown to be compromised and changed compared to heart failure 
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control patients. Theories regarding cellular impact have ranged from immune cell interactions 
with proteins adherent to the surface of the pump to the influence of super-physiological shear 
stresses on immune cell function. These same factors have also been shown to influence 
hemostasis as platelets interact with both adsorbed proteins on the surface of pumps and are 
subjected to high shear fields in current rotary VADs. This interaction of platelets with VAD 
surfaces at high shear rates have been studied in vitro, but typically only use end-point analysis. 
These previous studies became the foundation on which this current work was built. The main 
goal of this research was to investigate the response of immune cells and platelets to circulatory 
support with continuous flow ventricular assist devices. This was accomplished through a 
combination of clinical research and in vitro studies composed of the following objectives: 
1.5.1 Objective #1: Investigate the validity of immune cell paradigms developed with the 
HeartMate XVE LVAD in a current-generation device. 
Paradigms of selective T cell reduction and subsequent immunological imbalance were 
developed in a the now-obsolete HeartMate XVE LVAD. This paradigm has not been examined 
in patients implanted with a current-generation rotary device, and alternative paradigms have not 
been expressed. This objective will challenge one of the primary studies that inspired the body of 
literature outlining the selective T cell reduction hypothesis. 
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1.5.2 Objective #2: Investigate temporal leukocyte values, granulocyte activation and 
infection among several different contemporary VADs. 
Most contemporary studies investigating the near-constant risk of infection experienced by VAD 
patients focus the post-operative surgical wounds or the presence of a percutaneous driveline. 
Several in vitro studies have shown that innate immune cells may be susceptible to activation 
through interactions with artificial surfaces at elevated shear rates. This objective will investigate 
the influence of current VAD technology on patient granulocyte activation, alterations in 
leukocyte enumeration and infection.  
1.5.3 Objective #3: Investigate the effects of VAD support on hemostasis and thrombosis 
based on pre-operative liver dysfunction as well as between VAD types. 
This objective will challenge and enlarge the current body of knowledge available to the VAD 
clinical community through the investigation of hemostatic and thrombotic alterations in heart 
failure patients after implantation with contemporary rotary or pulsatile VADs. Cellular level 
effects as well as adverse event rates will be compared based on measures of patient pre-
operative hepatic dysfunction as well as between the type of device implanted.  
1.5.4 Objective #4: Develop a method for real-time visualization of platelet deposition 
onto opaque surfaces under physiologically-relevant flow conditions. 
Previous experiments of platelet deposition onto opaque surfaces used either non-physiologic 
platelet rich plasma as the perfusion fluid or relied on discreet timepoint observations to analyze 
 28 
the performance of the material. This objective will develop a method for real-time visualization 
of platelet deposition onto opaque surfaces under physiologically-relevant flow conditions. 
These in vitro experiments will serve as the foundation for evaluating alternative materials to 
titanium as the blood contacting surface in rotary VADs. 
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2.0  LYMPHOCYTE PROFILES AND ALLOSENSITIZATION IN PATIENTS 
IMPLANTED WITH THE HEARTMATE II LEFT VENTRICULAR ASSIST DEVICE 
2.1 INTRODUCTION 
The utilization of ventricular assist devices (VADs) to prolong life in advanced heart failure 
patients is established and expanding.[6] While many of the mechanical problems experienced 
during the procedure’s infancy have been greatly reduced, biologic complications continue to be 
seen. Among these complications, risk of infection may be the most troubling due to its 
prevalence throughout the implant period. VAD patients typically experience a greater number 
of infections than patients undergoing similar surgical procedures, with a resultant increase in 
infection-related mortality. Additionally, infection events may increase the risk of 
thromboembolic events, complicating anticoagulation monitoring and effectiveness.[99]  
The research community has recognized that cellular immunity in VAD patients is 
compromised, exhibiting an atypical and suboptimal immune response.[31] Several reports by 
Ankersmit et al outlined the effect of implantation of the HeartMate® XVE (HM XVE) VAD on 
T cell activation and apoptosis.[100-102] Early reports suggested that the CD4+ T cells of HM 
XVE patients had an increased susceptibility to activation-induced cell death.[100] This was 
later confirmed for HM XVE patients through a longitudinal study of differential lymphocyte 
counts which showed a significant selective reduction in CD4+ T cells over the first 2 months of 
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implantation (Figure 2.1).[101] Further studies showed the CD4+ T cell reduction may 
contribute to B cell hyperactivity and sensitization.[102] Few adaptive immune – cell studies 
have been conducted in contemporary rotary blood pumps. This study sought to re-examine 
some of the early T cell reports from Ankersmit et al in the currently – utilized rotary Heartmate 
II® (HMII) VAD in a comparably sized patient group. 
    
Figure 2.1: (Left) Progressive decline in CD4/CD8 T cell ratio following HeartMate XVE LVAD 
implantation. (Right) Decline of CD4 T cells and not CD8 T cells, with a relatively unchanged overall number 
of lymphocytes in patients implanted with the HeartMate XVE LVAD. From Ankersmit et al. [101] 
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2.2 PATIENTS AND METHODS 
2.2.1 Patient selection 
All study procedures and consent forms for data collection, blood collection and data analysis for 
this investigation were approved by the University of Pittsburgh’s Institutional Review Board 
(IRB).  
This study was a single-center investigation of patients implanted with the Thoratec® 
HeartMate II® LVAD (Thoratec Corp, Pleasanton, CA) at the University of Pittsburgh Medical 
Center (UPMC) Presbyterian Hospital between May 1, 2009 and January 1, 2010. Patient 
medical history, infection events, human leukocyte antigen (HLA) Class I and II levels, blood 
product administration and laboratory test values were gathered from an IRB-approved database 
at UPMC (Transplant Patient Management System). Additionally, patients consented to periodic 
blood draws for lymphocyte counts. Infection event determination followed the Interagency 
Registry of Mechanically Assisted Circulatory Support (INTERMACS) definitions.[9]  HLA 
levels were determined by enzyme-linked immunosorbent assay, with allosensitization defined 
as >10% at any time up to 1 year post-implantation.[103] Blood product exposure was measure 
for the first 48 h post-implant, with total blood product units (TBPU) equal to the sum of red 
blood cell (RBC), platelet, frozen plasma and cryoprecipitate units. 
2.2.2 Flow cytometric enumeration of circulating CD4+ and CD8+ T cells 
Enumeration of circulating T and B cells was performed according to established protocols using 
commercially available counting beads.[104] The antibodies used in this study were R. 
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Phycoerythrin-Cyanine 5 (RPE-Cy5)-conjugated CD45, fluorescein isothiocyanate isomer 1 
(FITC)-conjugated CD3 and either R. Phycoerythrin (RPE) – conjugated CD4 or CD8 (volumes 
per manufacturer’s specifications; all mouse anti-human; clones HI30, UCTH1, RPA-T4, and 
LT8, respectively; all from Abd Serotec, Raleigh, NC). Cal – Lyse Whole Blood Lysing Solution 
and PCB-100 Counting Beads were used per manufacturer’s instructions for the wash no – lyse 
cell counting technique (both from Invitrogen, Grand Island, NY). The cells were immediately 
analyzed with a 3-color FACScan (BD, Pleasanton, CA) and processed with WINList software 
(Verity Software House, Topsham, ME) per the counting bead manufacturer’s instructions for 
data collection and analysis. 
2.2.3 Statistical Analyses 
All data are presented as mean ± standard error of the mean unless noted. Paired-sample T-tests 
were used for comparison of pre-operative and 30-day variables, and independent T-tests were 
used for comparison of these same variables to historical means from Ankersmit et al.[101] 
Friedman’s ANOVA was used for non-normally distributed temporal data, with Wilcoxon post 
hoc analyses using Bonferroni corrections. Sensitization and blood product exposure were 
analyzed by Mann-Whitney U test. Statistical significance was assumed at P<0.05. All statistical 
tests were performed with SPSS v16.0 (IBM Corp, Armonk, NY). 
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2.3 RESULTS 
2.3.1 Patient demographics 
A total of 8 patients were followed for this study; however, only 2 were available for the pre-
implant and 30 day timepoints. The pre-operative characteristics for these 8 patients are 
presented in Table 2.A. 
 
Table 2.A: Patient demographics and heart failure information for lymphocyte studies 
Demographics
Implant Age (yr) 47 ± 5
Sex (% male) 88 %
Destination Therapy (Y) 63 %
Diabetes % 40 %
Smoker % 80 %
Hemodynamics
BSA (m2) 2.3 ± 0.1
CO (L/min) 4.6 ± 0.4
CI (L/min/m2) 2.0 ± 0.1
LVEF % 12.9 ± 1.9
BP Mean 80 ± 3
PAP Mean 34 ± 2
CVP 10 ± 2
Pre-op and Concomitant Support
Milrinone (mg) 0.3 ± 0.1
IABP % 50 %
IABP (avg days) 4.5 ± 1.3
ECMO % 13 %
ECMO (days) 5
RVAD % 0 %
Pre-operative Diagnosis
Dilated Myopathy: Idiopathic 50 %
Dilated Myopathy: Ischemic 50 %
Average ± Standard Error of the Mean, or Percent
BP=Blood Pressure     BSA=Body Surface Area     CI=Cardiac Index
CO=Cardiac Output     CVP=Central Venous Pressure     
DT=Destination Therapy     ECMO=Extracorporeal Membrane Oxygenation     
IABP=Intra-Aortic Balloon Pump     LVEF=Left Ventricular Ejection Fraction     
PAP=Pulmonary Artery Pressure     RVAD=Right Ventricular Assist Device  
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2.3.2 Leukocyte and T cell population changes following HeartMate II implantation 
Data from a study by Ankersmit et al. that compared T cell populations between a heart 
failure control group and patients implanted with the HM XVE at post-operative day (POD) 30 
are reproduced in Table 2.B.[101] A similar analysis was performed for the HMII patients in the 
current study pre-operatively (serving as internal controls) and at POD 30. The mean historical 
values from Ankersmit et al. were then compared to patients in the current study at the same 
timepoints. While Ankersmit et al. found that patients implanted with the HM XVE exhibited 
relative lymphopenia (P=0.043) and a selective decrease in CD4+ T cells (P=0.009) resulting in 
a decrease in the CD4/CD8 T cell ratio (P=0.0008), the HMII patients in the current study 
showed no significant changes in any of these parameters. Comparing the data from Ankersmit 
et al. groups to the patients in this study, we found no differences between the groups except that 
HM XVE patients had significantly lower CD4+ T cell counts than the HMII patients at POD 30 
(P=0.001).   
 
Table 2.B: Comparison of T cell populations in HMII and HeartMate XVE patients (Ankersmit et al [98]) 
P P P P
Lymphocytes (%) 17.0 ± 2.0 9.6 ± 2.4 0.043 17.6 ± 4.5 13.3 ± 2.5 0.250 0.888 -8.1 9.3 0.312 -3.8 11.3
CD4/CD8 Ratio 4.1 ± 0.4 2.0 ± 0.3 <0.001 2.8 ± 0.4 2.5 ± 0.3 0.945 0.060 -2.6 0.1 0.209 -0.3 1.3
CD4 Levels (n/µL) 624 ± 59 374 ± 6 0.009 744 ± 204 628 ± 82 0.945 0.453 -203 442 0.001 114 393
CD8 Levels (n/µL) 194 ± 32 230 ± 93 0.260 272 ± 58 290 ± 60 >0.999 0.224 -51 206 0.638 -202 322
   Values are Mean ± SEM
HeartMate XVE (Ankersmit et al) HeartMate II HeartMate XVE v HeartMate II
NYHA Class IV HeartMate XVE Pre-Implant HeartMate II
(N=20) (N=12) (N=8) (N=8) 95% CI 95% CI
Controls Patients Controls Patients Controls VAD Support
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2.3.3 Temporal T cell changes following HeartMate II implantation 
When these observations were examined at POD 120, no difference was found in CD4/CD8 T 
cell ratio, CD4+ or CD8+ T cell counts, or lymphocyte composition in HMII patients (Figure 
2.2 A, B, C). There was a slight decrease in CD4+ T cell counts at POD 30 and 60, but the 
difference was not significant compared to pre-operative levels and was normalized by POD 90 
(Figure 2.2 B). The CD8+ T cell count was nearly constant during the study period with little 
variation among timepoints (Figure 2.2 B). As a result, the slight changes in CD4+ T cell counts 
were reflected in the CD4/CD8 T cell ratio, which was also not significantly different over the 
study period (Figure 2.2 A). 
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 Figure 2.2: Changes in lymphocyte populations following HMII implantation. A) Ratio of circulating CD4+ T 
cells and CD8+ T cells. B) Absolute cell counts of circulating CD4+ T cells and CD8+ T cells. C) Percentage of 
circulating lymphocytes consisting of CD4+ T cells, CD8+ T cells and all T cells. Mean plus standard error of 
the mean for all values. N=8 for all data points. 
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2.3.4 Infection and sensitization rates in patients implanted with the HeartMate II 
No patients had an active infection at the time of implantation. Following device placement, 
seven infection events were reported during the study period. During the first 30 days of support 
there were two incidents of sepsis and one localized non-device related event (pneumonia). The 
next 30 days had one incidence of pneumonia and one localized non-device related (infected 
sacral decubitus wound) event. During the intervals of POD 61 to 90 and POD 91 to 120 there 
was one reported incidence of sepsis. Of the 6 patients followed out to POD 120, 3 had at least 
one reported infection during the study period. 
HLA levels were available for 7 patients, of which 29% were sensitized (Patient 1: Class 
I > 60%, Class II > 30%; Patient 2: Class I > 90%, Class II > 75%; no other patients > 6%). 
Average blood product exposure was 3.1 ± 1.4 units RBCs, 5.6 ± 3.7 units platelets, and 15.0 ± 
7.4 TBPU. When grouped according to sensitization, the sensitized patients had significantly 
more platelet exposure (19.5 ± 3.5 vs 0.0; P = 0.048) but not RBC (8.5 ± 0.5 vs 1.0 ± 0.4; P = 
0.095) or TBPU (39.5 ± 11.5 vs 5.2 ± 3.0; P = 0.095). 
2.4 DISCUSSION 
The proposed mechanisms for VAD patient vulnerability to infectious agents have spanned from 
simple barrier breakdown at the driveline interface to complex hemodynamic shear forces 
affecting viability among circulating monocytes and granulocytes.[105-107] A series of studies 
with HM XVE patients focused on selective reductions in T cell populations. Ankersmit et al 
found a significant decrease in CD4+ T cells, possibly from CD95 (Fas) - mediated 
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apoptosis.[100,101] Subsequent reports revealed that the CD4+ T cell depletion may have caused 
non-specific B cell hyperactivity in these patients.[102] One study concluded that with the 
simultaneous combination of increased risk of infection and increased allo-sensitization, the 
closest disease models to HM XVE implantation are systemic lupus erythematotus and human 
immunodeficiency virus type 1.[101] The effects of this immune state in HM XVE patients have 
also been studied, revealing longer transplant wait times and hospital stays, both of which 
increase health risks and costs to the patient.[108,109] 
However, the HM XVE has been replaced by the HMII rotary VAD. Device size, 
driveline diameter, battery charge time and mechanical lifespan were all improved through the 
rotary design. Despite this change, no studies on adaptive immune response following rotary 
VAD implantation have been performed. 
This study attempted to replicate the initial reports from Ankersmit et al. in HMII rotary 
VAD patients.[100,101] Table 2.B shows that we were able to confirm much of the information 
presented by Ankersmit et al. The control and pre-operative values between each study are not 
different, suggesting that similar populations were represented in each. The implanted cohorts in 
each study were also not different in almost all of the parameters followed, including percent 
lymphocytes, CD8+ T cell count and CD4/CD8 ration. However, we were not able to confirm 
the main thesis of the Ankersmit et al. studies of the selective reduction of CD4+ T cells.[101] 
CD4+ T cell counts in HMII patients did not change following device placement (P=0.945), 
while HM XVE patients exhibited a significant decrease (P<0.001). Additionally, HMII and HM 
XVE patients had similar pre-operative CD4+ T cell counts (P=0.453) but HMII patients had 
higher counts following implantation (P=0.001). When followed to POD 120, HMII patients 
continued to exhibit no difference in CD4+ T cells compared to pre-operative values (Figure 2.2 
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B). Given this finding, it is not surprising that HMII patients also failed to exhibit the significant 
drop in CD4/CD8 ratio following VAD implantation found in the Ankersmit study (Table 2.B, 
Figure 2.2 A). The control and pre-operative T cell counts and CD4/CD8 ratio from Ankersmit 
et al. and this study were similar to other descriptions of patients undergoing cardiac surgery but 
were markedly lower than reports of healthy adults or general surgery patients.[110-113] 
These results are not unexpected as the surfaces of the HM XVE and the HMII were 
designed to interact differently with the blood of the implanted patient.[114] The pulsatile HM 
XVE had rough surface textures throughout the device which promoted endothelial deposition. 
(Figure 2.3 A, B) While this unique approach allowed for an aspirin-only anti-thrombotic 
regimen, the biologic mechanisms involved were complex.[47] Additionally, residual volumes 
between beats and recirculation zones common in pulsatile pumps may have contributed to 
leukocyte entrapment and adhesion. The surfaces of explanted pumps were found to contain 
activated cells from macrophage and dendritic lineages, as well as endothelialization.[79,115] 
(Figure 2.3 C) Overstimulation of CD4+ T cells from these antigen presenting cells on the HM 
XVE surface may have helped to trigger the apoptotic response found by Ankersmit et al. 
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Figure 2.3: SEM micrographs of the textured blood contacting surfaces of the HeartMate XVE LVAD. (A) 
Sintered titanium. (B) Textured flexible polyurethane. (C) Histological cross section of the organized 
biological material found on the sintered titanium portion of the LVAD after 41 days of implantation. 
Mononucleated cells were apparent on the upper luminal side of the cross section. STM, Sintered Titanium 
Microspheres; ITP, Integrally Textured Polyurethane. From Dasse et al. [116] 
 
In contrast, the HMII is polished over the majority of the flow path to minimize cellular 
adhesion, with sintered titanium surfaces limited to the inflow cannula and the bends leading into 
and out of the pump. The continuous flow profile of this pump may reduce the time of contact 
between circulating leukocytes and the textured segments, limiting the quantity of leukocytes on 
the device surface. The high shear stresses found in the blood flow path of the HMII may also 
prevent leukocyte adhesion and motility on the surface. When compared to the HM XVE, the 
HMII environment may reduce the potential for accumulation and interaction of antigen 
presenting cells and CD4+ T cells. 
Despite no changes in adaptive immune cell profiles, the occurrence of infection among 
HMII patients continues to be seen. Half of the patients within 120 days of implant had an 
infection event, usually resulting in longer hospitalization time and increased risk to the patient. 
A B C 
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Of particular concern were two incidences of sepsis after POD 60, occurring past the usual 
surgical recovery period and in the absence of other procedures. 
One consequence suggested in the Ankersmit et al study of the selective decrease of 
CD4+ T cells in HM XVE patients was allosensitization from hyperresponsive B cells.[102] 
Schuster et al reported that in HM XVE patients, 43% were sensitized to Class I antibodies and 
33% were sensitized to Class II antibodies, which was higher than seen in heart failure control 
patients.[102] Other similar reports for HM XVE patients reported sensitization rates post-
implantation to be between 28 and 63%.[117-119] In contrast, two studies comparing 
sensitization of HM XVE and HMII patients found that HMII patients were significantly less 
likely to become sensitized (8% and 9% for HMII v 28% and 45% for HM XVE) while a third 
found virtually no difference in sensitization rates or in post-transplant rejection 
outcomes.[103,120,121] Some attribute this difference to the presence of the HM XVE device, 
while others have suggested that blood product exposure (specifically platelet administration) 
from the procedure may be a confounding factor.[119,122] Even though HMII patients in this 
study did not exhibit the same pattern of T cell reduction found in reports of HM XVE patients, 
the rate of sensitization was still relatively high. However, examination of blood product 
exposure in the two sensitized patients suggests this may have been a contributing factor as both 
received ≥ 28 units of platelets compared to no platelet administration in the other 5 patients.  
2.5 LIMITATIONS 
A primary limitation of this study is that it was performed at a single institution study and 
consisted of a relatively small number of patients; as such, the hypothesis tests have an increased 
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susceptibility to type II errors. While the inclusion of more patients is warranted to confirm our 
results, the design of this study was guided by the reports by Ankersmit et al. and our 
methodology and study size does not represent a major deviation from the previous 
work.[100,101] A simultaneous comparison of the two devices would have been ideal, but the 
historical comparison was necessary as the HM XVE is no longer available for implantation. The 
pre-operative values from the patients in our study were not different from the Ankersmit et al. 
control subjects, suggesting similar populations were examined in both studies.[101] 
Additionally, the sharp and sustained decline in CD4+ T cells exhibited by the HM XVE cohort 
would be difficult to hide if this effect was indeed present in the HMII patients followed. 
Selection bias could also have been present in this study, although none of the patients presented 
with conditions known to influence T cell counts other than heart failure. Further investigation of 
the influence of HMII implantation on immune cells may help our understanding of the 
challenges faced by these patients, although this report and reports from others suggest that the 
focus may need to turn towards the innate immune cells.[106,107] 
2.6 CONCLUSIONS 
HMII patients do not exhibit the selective CD4+ T cell reduction or a reduction in the CD4/CD8 
T cell ratio previously reported in HM XVE patients. Despite these improvements in T cell 
profiles, infection was still a substantial risk during the study period, particularly sepsis. 
Sensitization was also problematic, though the cause in this instance may have been from donor 
platelet exposure. Thus, despite increased experience with VADs and technological advances 
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afforded by rotary VADs, HMII patients may continue to be at risk to the same immunological 
adverse events as previous-generation devices. 
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3.0  TEMPORAL LEUKOCYTE NUMBERS AND GRANULOCYTE ACTIVATION 
IN PULSATILE AND ROTARY VENTRICULAR ASSIST DEVICE PATIENTS 
3.1 INTRODUCTION 
(Note: a majority of this chapter was previously published as: Woolley JR, Teuteberg JJ, 
Bermudez CA, Bhama JK, Lockard KL, Kormos RL, Wagner WR. Temporal leukocyte numbers 
and granulocyte activation in pulsatile and rotary ventricular assist device patients. Artif Organs 
2014; in press.) 
Ventricular Assist Devices (VADs) have become an established treatment for advanced heart 
failure, prolonging the life of patients when used as a bridge to transplantation or as destination 
therapy. Despite technological advances and increased experience, VAD patients are still 
vulnerable to infection and hemostatic complications such as bleeding and thromboembolism. 
While the mortality from bleeding or thromboembolism has been shown to decrease substantially 
after the first 30 days of support, infection is an ongoing risk while on mechanical support.[123-
125] The speculated causes for the occurrence of infection range from the existence of a 
percutaneous line providing a pathway for infectious agent migration, to impaired leukocyte 
function from interactions with the foreign surfaces of some VADs.[100,124]  
Most previous VAD immunological studies included patients with prior generations of 
pulsatile pumps, many of which are no longer available, rather than continuous flow pumps, 
 45 
which are currently the dominant technology. This is significant in that the design of 
contemporary rotary VADs is considerably different than pulsatile VADs and may lead to a 
different leukocyte response from that reported in previous studies.[106,107] Additionally, few 
studies have presented temporal leukocyte counts [126], as most investigators report leukocyte 
counts at a specific post-operative time point where they are incorporated as risk factors in 
outcome scores.[127] The effects of VAD support on granulocytes have also been studied, but 
only one study followed granulocyte populations over time [126] and no studies have reported 
the degree of granulocyte activation through the expression of macrophage antigen-1 (MAC-1). 
The objective of this study was to investigate the influence of current VAD technology on 
patient granulocyte activation, leukocyte counts and infection.  
3.2 PATIENTS AND METHODS 
3.2.1 Patients and devices 
All study procedures and consent forms for data collection, blood collection and data analysis for 
this investigation were approved by the University of Pittsburgh’s Institutional Review Board 
(IRB).  
This study was a single-center investigation which consisted of patients who underwent 
placement of a long-term left ventricular assist device (LVAD) (intended length of support >14 
d) at the University of Pittsburgh Medical Center (UPMC) Presbyterian Hospital between 1999 
and 2011. Patients were excluded if they had a temporary LVAD, had a long-term right 
ventricular assist device implanted, or were supported < 30 d by the device. Three different 
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devices were included in this study: the Thoratec® PVAD™ pneumatic device (PVAD; Thoratec 
Corp, Pleasanton, CA), and the Thoratec® HeartMate II® (HMII; Thoratec) and HeartWare® 
HVAD ® (HW; HeartWare Inc, Framingham, MA) rotary blood pumps. All patients had 
traditional driveline tunneling with partial velour exposure. Patient medical history, infection 
events and hospital or outpatient laboratory test values were collected from the IRB-approved 
Transplant Patient Management System database at UPMC. A subset of these patients that were 
implanted between 2009 and 2011 were included in an investigation of granulocyte activation 
levels and consented to providing blood samples pre-operatively and throughout device support. 
Data from this subset is presented to POD 30 and POD 120 to present short- and long-term 
perspectives; whereas data were available for all patients in the subset to at least POD 30, some 
lab values were unavailable when followed to POD 120 and these patients were not included in 
the long-term analysis. The Interagency Registry of Mechanically Assisted Circulatory Support 
(INTERMACS) definition for an infection event was used to determine the occurrence of 
infections.[9]  
3.2.2 Flow cytometric determination of MAC-1 expression on circulating granulocytes 
Flow cytometry was performed by a modified method from Donnenberg et al.[128] Within 4 hr 
of collection 100 mL citrated (Vacutainer, BD, Pleasanton CA) whole blood was placed in 
polystyrene tubes and lysed by the addition of 2 mL ammonium chloride lysis buffer. The lysed 
solution was centrifuged at 400xg for 10 min and, following removal of supernatant, the cells 
were washed with 1 mL Dulbecco's Phosphate-Buffered Saline without Ca++ or Mg++ with 4% 
calf bovine serum (Staining Buffer; MP Biomedicals LLC, Solon, OH) and centrifuged again at 
400xg for 10 min. The leukocyte pellets were decanted dry and then stained with 2 µL 
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fluorescein isothiocyanate isomer 1-conjugated mouse anti-human CD15 (clone MEM-158) and 
2 µL either R. Phycoerythrin-conjugated mouse anti-human MAC-1 (CD11b, clone ICRF44) or 
a R. Phycoerythrin-conjugated mouse IgG1 isotype control (all from Abd Serotec, Raleigh, NC), 
incubated for 20 min in the dark and washed with 1 mL Staining Buffer. Following 
centrifugation at 400xg for 10 min, the cells were resuspended in 500 µL 1% paraformaldehyde 
(Sigma, St. Louis, MO) and stored at 4°C (<36 hr) until analyzed. At least 4000 CD15+ events 
were collected on a 3-color FACScan (BD) and analyzed with WINList flow cytometry software 
(Verity Software House, Topsham, ME). Granulocytes expressing MAC-1 were defined as 
CD15+ cells, exhibiting the characteristic granulocyte forward- and side-scatter values, that had 
displayed MAC-1 binding higher than 98% of the isotype control as measured through 
fluorescence intensity.  
3.2.3 Infection events and peak granulocyte MAC-1 expression 
The influence of infections as a confounding factor on peak granulocyte MAC-1 expression in 
HMII patients was investigated by comparing the average pre-operative MAC-1 expression 
levels to average values during an infection and average peak levels which were not during an 
infection. The 3 groups in this comparison are “Mean Pre-operative Value”, “Mean Infection 
Value” and “Mean Peak Noninfection Value”. “Mean Pre-operative Value” is defined as blood 
samples that were collected and analyzed within 5 days prior to implantation. No patients 
exhibited signs of infection prior to device placement. “Mean Infection Value” were from blood 
samples withdrawn an average of 3.9 days after a confirmed infection event and before the 
apparent resolution of the event. Blood samples for the “Mean Peak Noninfection Value” were 
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collected during periods when the patient was not actively infected (at least 14 days before a 
confirmed event).  
3.2.4 Statistical analyses 
All continuous data is mean ± standard error of the mean. All continuous data were analyzed by 
ANOVA with Bonferroni post hoc tests or Kruskal-Wallis test with Mann-Whitney U post hoc 
analysis (and Bonferroni correction). Categorical data was tested with Chi-square (using the 
Likelihood Ratio statistic). Temporal studies were analyzed by repeated measures ANOVA with 
Bonferroni post hoc testing. The analysis of infection events on granulocyte MAC-1 expression 
in HMII patients contained 5 patients that experienced at least one infection during implantation; 
however, 3 of the 5 patients experienced two infections. In instances of two infection events, the 
second infection event was used in the comparison to allow for repeated measures ANOVA tests 
without affecting the average for the group. Statistical significance was assumed at P<0.05. All 
statistical tests were performed with SPSS v16.0 (IBM Corp, Armonk, NY). 
3.3 RESULTS 
3.3.1 Patient demographics, bypass time, chest tube output and blood product exposure 
A total of 56 patients were followed for this study, with a subset of 20 patients that had 
additional blood collected for granulocyte activation determination. Most patients were male 
(77%) with a mean age of 55 and a pre-operative diagnosis of ischemic cardiomyopathy (46%). 
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The only significant pre-operative differences between the patients implanted with each device 
were implant age, pre-operative diabetes, and mean blood pressure (Table 3.A). The operation 
rates for all pumps were within each manufacturer’s suggested range, and did not vary greatly 
over the course of the study. For the HMII cohort, the median rotations per minute (RPM) was 
9400 at POD 14 and POD 120, with a maximum of 10,200 and a minimum of 8800. HW patients 
had median RPMs of 2800 at POD 14 and 2880 at POD 120, with a maximum of 3160 and a 
minimum of 2500. PVAD patients had a median beats per minute rate of 82 at POD 14 and POD 
120, with a maximum of 99 and minimum of 64. No differences were found between any group 
for cardiopulmonary bypass (CPB) time, chest tube output during the first 24 h post-implant, or 
blood product exposure during the first 48 h post-operation (Table 3.B). 
 
Table 3.A: Macrophage antigen-1 (MAC-1) study patient demographics and heart failure information 
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Table 3.B: Cardiopulmonary bypass support, postoperative bleeding, and blood product exposure* 
 
3.3.2 Temporal leukocyte numbers and infection events 
PVAD patients had significantly different temporal trend of white blood cell counts than HW 
patients (P=0.036) (Figure 3.1 A). Each group of patients significantly peaked on POD 14 above 
all other timepoints (P<0.001) and above the intra-hospital normal range. By POD 60, white 
blood cell counts in patients from each group had decreased significantly below the pre-operative 
counts. The percentage of leukocytes consisting of granulocytes in each group exhibited a slight 
peak at POD 14 but remained relatively flat for the study period (Figure 3.1 B). Hematocrit 
significantly dropped below all other timepoints at POD 14 (P<0.006) and remained lower than 
pre-operative levels to 60 (P<0.012) (Figure 3.1 C).  
Infection events per patient-day were concentrated in the first 30 days of device support, 
though the PVAD patients exhibited a biphasic trend (Figure 3.1 D). The HW group experienced 
a significantly lower number of infection events per patient during the study period than the 
HMII and PVAD groups (Table 3.C). The HMII and HW VAD patients were then combined to 
form a continuous flow VAD group, and infection events for this group were compared to the 
pulsatile flow PVAD patients. The continuous flow VAD patients (N=44) did not experience a 
different number of infections per patient during the study versus the pulsatile PVAD patients 
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(N=12) (0.98±0.25 versus 1.42±0.36, P=0.099). The continuous flow patients also did not 
experience a different number of sepsis events or localized non-device infections than the 
pulsatile group (respectively: 0.27±0.09 versus 0.17±0.11, P>0.999; 0.64±0.18 versus 0.75±0.28, 
P=0.770). However, the number of driveline infections per patient were significantly lower for 
continuous flow patients than for pulsatile patients (0.05±0.03 versus 0.42±0.23, P=0.007). 
 
 
Figure 3.1: Leukocyte and hematocrit changes and incidence of infection events in HMII, HW and PVAD 
patients following implantation of the device. (A) White blood cell numbers. (B) The percentage of white 
blood cells consisting of granulocytes. (C) Total hematocrit. (D) Infection events per day of patient support. 
Mean plus standard error of the mean for continuous data. Normal ranges are intrahospital values. The “0” 
on the abscissa indicates preoperative values. HMII, HeartMate II; HW, HeartWare; PVAD, Thoratec 
pneumatic VAD. 
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Table 3.C: Infection events in ventricular assist device patients to postoperative day 120 
 
3.3.3 Granulocyte MAC-1 expression and infection events in a subset of patients  
MAC-1 expression on circulating granulocytes had significantly different trend in HMII patients 
than HW or PVAD patients when evaluated to POD 30 (P<0.035) and HW patients to POD 120 
(P=0.014) (Figure 3.2 A, B). The HMII patients exhibited a 2.3 fold increase in MAC-1 
expression on POD 14 over pre-operative levels and stayed elevated to POD 30 (Figure 3.2 A). 
When followed to POD 120, the HMII patients had a 2.5 fold increase (from pre-operative 
levels) in MAC-1 expression on POD 14 and remained elevated to POD 60 (Figure 3.2 B). 
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 Figure 3.2: Macrophage antigen-1 (MAC-1) expression on circulating granulocytes in a subset of ventricular 
assist device patients following implantation. (A) MAC-1 expression in all three devices evaluated to 1 month 
post-implant. (B) MAC-1 expression in HMII and HW patients to postoperative day 120. Data presented as 
mean plus standard error of the mean. The “0” on the abscissa indicates preoperative values. HMII, 
HeartMate II; HW, HeartWare; PVAD, Thoratec pneumatic VAD. 
 
HMII patients that experienced an infection over the course of study enrollment were 
examined to determine the effect of infection events on granulocyte MAC-1 expression (Figure 
3.3). MAC-1 expression during an infection event exhibited almost no increase over pre-
operative values (9.6% to 9.0%, respectively); however, these same patients had peak 
granulocyte MAC-1 expression at levels >2.5 fold higher than those pre-operatively or during an 
infection (24.2%; P<0.015). The average POD of infection for these patients was 54 ± 22 d. 
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 Figure 3.3: Granulocytes expressing macrophage antigen-1 (MAC-1) in HMII patients who experienced as 
least one infection event during study enrollment. Data presented as mean ± standard error of the mean. 
HMII, HeartMate II. 
3.4 DISCUSSION 
This study presents a window into the leukocyte and infection profiles of pulsatile and rotary 
VAD patients out to 120 days post-implantation, providing a few notable findings. First, white 
blood cell counts increased significantly in the early post-operative period, despite a 
simultaneous decrease in hematocrit (Figure 3.1 A, C). While other authors have found similar 
trends with patients having undergone coronary artery bypass graft or heart valve surgeries 
[110,111], both the white blood cell and hematocrit effects described in these studies returned to 
normal or pre-operative values by POD 5 and were not as pronounced as was found for patients 
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in this report. This suggests that the surgery- and device- induced systemic response may be 
substantial, as post-operative bleeding and reduction of the inflammatory response would be 
expected to reduce circulating leukocytes by this timepoint. Second, HMII patients experienced a 
similar rate of infection to the Thoratec PVAD to POD 120, despite a greatly reduced 
percutaneous driveline exit area (and significantly less driveline infections) (Table 3.C). In 
contrast, HW patients had significantly fewer infection events than either the HMII or the PVAD 
patients, and the post-operative increase in white blood cell counts was lower than the PVAD 
group. In the PVAD and HMII patients, most infections occurred during the first 30 days of 
support, but they continued to be susceptible throughout the study (Figure 3.1 D). The peak rates 
of infection for all VAD patients coincided with significant increases in white blood cell counts 
(above the normal range) and an upward trend in relative granulocyte concentration (Figure 3.1 
A, B). This result is in line with the observation that leukocyte proliferation is a hallmark of 
infection. In this setting, infectious agents are presented with increased opportunities to find safe 
harbor and flourish on devitalized tissues and along the synthetic surfaces of the percutaneous 
driveline and indwelling catheters in the peri-operative period. The concentration of infections 
during the first 30 days of support agrees with reports [123,129] and hazard models [130,131] 
seen in studies with other devices. 
Granulocytes are an important first line of defense against infection, migrating from the 
vasculature to sites of injury to combat infectious agents. MAC-1 is an adhesion molecule 
expressed on stimulated granulocytes that mediates migration of the cell from the circulation into 
inflamed tissue. Upregulation of granulocyte MAC-1 expression in cardiovascular interventions 
is commonly associated with CPB circuit perfusion and sepsis as a biomarker for systemic 
inflammation.[132,133] Extravasated granulocytes (following MAC-1 expression) release 
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enzymes and reactive oxygen species that damage tissue and have been linked to increased 
edema and organ damage following surgery.[134,135]  
Despite growing evidence of altered immune cell function in VAD patients, there is a 
paucity of information on granulocyte activation and the few papers that discuss it are 
incomplete or inconclusive. Diehl et al investigated the prevalence of leukocyte-derived 
microparticles in several rotary or pulsatile VADs at 144 days post-implantation compared to a 
historical control population.[136] Although the authors found that VAD patients had 
significantly elevated levels of circulating microparticles expressing MAC-1, the cellular origins 
of the microparticles were not reported. The authors discussed the possibility of increased 
microparticles caused by elevated wall shear stresses in various VADs disrupting the immune 
system but did not distinguish the results by type of circulatory support or provide information 
on infections for these patients. 
Loebe et al reported elevated circulating levels of various inflammatory biomarkers such 
as complement anaphylatoxins, cytokines and polymorphonuclear leukocyte elastase (PMNE, an 
indicator of granulocyte activation) compared to normal values for patients implanted with the 
pulsatile Novacor® or the rotary MicroMed DeBakey® VAD.[137] While these investigators 
found that C5a and interleukin-6 were significantly increased in the rotary VAD population 
compared to the pulsatile cohort, PMNE values were nearly identical between the two groups. 
Additionally, each variable was condensed from 3 months of timepoints into a single averaged 
post-operative value and not compared to pre-operative levels, limiting the usefulness of this 
information.  
In this study, HMII patients exhibited a rise in granulocyte MAC-1 expression on POD 
14 which remained elevated to POD 60 (Figure 3.2 B). Similarities among temporal trends for 
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MAC-1 expression, white blood cell counts and infection events in HMII patients initially 
suggested that the elevated MAC-1 expression may be the result of blood samples withdrawn 
during active infections (Figures 3.1 A, D and 3.2 A, B). However, closer inspection of HMII 
patients that experienced at least one infection event revealed that peak MAC-1 expression 
occurred in the absence of infection (Figure 3.3).  
Studies involving patients exposed to CPB circuits report only short-term leukocyte 
activation, with most subjects returning to pre-operative levels within 48 hours.[138,139] The 
current study reveals that HMII patients experienced granulocyte MAC-1 expression elevated to 
levels comparable to that with CPB patients, but these findings continued to 60 days post-
procedure.  To the authors’ knowledge, this is the first report demonstrating persistent circulating 
activated granulocytes this long after the early post-operative period. This study also suggests 
that the extended MAC-1 elevation phenomenon for the group of VADs studied was specific to 
the HMII pump and not attributable to differences in CPB time or blood product exposure 
(Figure 3.2 A, B; Table 3.B). The MAC-1 data presented in this study does not appear to be 
predictive of infection events (Figure 3.3), but rather offers some insight into the underlying 
cellular immunological health of the patient. The prolonged expression of MAC-1 on circulating 
granulocytes has been shown by others to be detrimental to patients. The potential impact of 
ongoing and elevated granulocyte extravasation could help to explain prolonged tissue edema 
and organ dysfunction sometimes seen in patients supported by the HMII (such as pulmonary 
edema and kidney insufficiency). Expression of MAC-1 has been reported to be a modulator of 
granulocyte apoptosis, shortening lifespan and facilitating sequestration and clearance in the 
spleen.[140] Similarly, Shive et al found increased neutrophil apoptosis following exposure to 
high fluid shear stresses, such as those assumed to be experienced in a continuous flow 
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pump.[107] While higher rotational speeds within an individual device is related to shear stress, 
comparisons of shear forces between devices based on pump speed was not considered in this 
study as differences in pump architecture is a critical variable in the estimation of fluid shear 
stress, and the local shear profiles at varying speeds in blood for each pump design were not 
available. 
The similar occurrence of infection events between the HMII and PVAD patients might 
be unexpected considering the substantially smaller exit site of the HMII driveline (Table 3.C). 
The increased levels of granulocyte MAC-1 expression found in HMII patients may have 
negatively affected granulocyte reactivity and responsiveness in these patients. MAC-1 induced 
apoptosis of granulocytes could help to explain the relatively high incidence of infection among 
HMII patients during the first 60 days of implantation. In contrast, the HW device may have 
advantages over the other devices in that it has a smaller percutaneous exit site than the PVAD, 
and its patients had significantly lower levels of granulocyte MAC-1 expression than those of the 
HMII. Both of these factors could contribute to HW patients experiencing significantly less 
infection events than either the PVAD or HMII patients. It appears that there may be VAD 
design factors other than driveline exit site contributing to a risk of infection. 
3.5 LIMITATIONS 
This was a single institution study consisting of a relatively small number of patients; a larger 
multi-center study is warranted. The methodology of this study focused on assessing the 
prolonged effects of VAD implantation on circulating immune cells. Only patients supported for 
> 30 d were included in the study, which may have contributed to some selection bias. However, 
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recent INTERMACS data suggest this still represents > 85% of all VAD patients.[6] Another 
limitation with this study was that only bridge-to-transplant patients could be implanted with the 
HW or PVAD pumps, which resulted in shorter enrollment periods in the prospective study due 
to pump explant or transplantation. Additionally, the PVAD was rarely utilized as an LVAD-
only device, decreasing the number of available patients that were included in this cohort. All of 
these factors contributed to a smaller statistical power for the subset of patient whose granulocyte 
activation levels were followed, especially when evaluated to POD 120. Infectious event data 
was also limited by the size of the study, and confirmation of differences in infection rates 
between devices would require more patients followed for a longer period of time. Only 
driveline tunneling with partial velour exposure was used during the study. Other techniques 
have been described that may improve infection rates [141]; however, the presence of infection 
did not contribute to the increased MAC-1 levels in HMII patients (Figure 3.3). Another study 
limitation was that other parameters, such as markers of inflammation or granulocyte apoptosis 
were not measured. Simultaneous measurement of tissue edema as well as plasma interleukin-2, 
interleukin-6, complement anaphylatoxins and tissue necrosis factor-α along with granulocyte 
MAC-1 expression would be of interest in future studies.  
3.6 CONCLUSIONS 
Alterations in leukocyte numbers and granulocyte activation experienced by VAD patients may 
be device-specific. HMII patients experienced a significantly different trend of circulating 
granulocyte MAC-1 expression compared to PVAD and HW patients to POD 30, and HW 
patients to POD 120, as well as substantially longer elevation than was reported in temporal 
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studies involving CPB circuits. Extravasation and apoptosis of activated granulocytes may 
contribute to persistent edema and continued infection risk among HMII patients. In contrast, 
HW patients exhibited little granulocyte activation and significantly less infection events. VAD 
design may thus influence circulating immune cell activation and infection risk, although the 
specific relationship between this activation and infection is not known.  
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4.0  PRE-OPERATIVE LIVER DYSFUNCTION INFLUENCES BLOOD PRODUCT 
ADMINISTRATION AND ALTERATIONS IN CIRCULATING HEMOSTATIC 
MARKERS FOLLOWING VENTRICULAR ASSIST DEVICE IMPLANTATION 
4.1 INTRODUCTION 
(Note: a majority of this chapter was previously published as: Woolley JR, Kormos RL, 
Teuteberg JJ, Bermudez CA, Bhama JK, Lockard KL, Wagner WR. Pre-operative liver 
dysfunction influences blood product administration and alterations in circulating hemostatic 
markers following ventricular assist device implantation. Eur J Cardiothorac Surg 2014; in 
press.) 
The use of ventricular assist devices (VADs) to treat end-stage heart failure is widespread and 
continues to grow.[6] Bleeding complications in the peri-operative period following VAD 
placement are still common, due in part to prior operations, pre-implant coagulation status, 
chronic hepatic congestion and the need for anticoagulation and anti-platelet agents post-
implantation.[6] Bleeding events may also have far reaching effects as some studies have linked 
blood product consumption to a variety of complications such as increased risk of mortality, 
acute lung injury, concomitant right ventricle dysfunction and allosensitization.[24,142]  
Recent publications have demonstrated a correlation between the Model for End-Stage 
Liver Disease (MELD) score with peri-operative bleeding and post-operative morbidity and 
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mortality.[143-145] High MELD scores may predict the development of multi-organ failure and 
hepatic congestion, leading to hemostatic imbalance and disregulation.[145,146] The objective 
of this study was to investigate the utility of MELD scores to predict post-implant circulating 
hemostatic markers, blood product consumption and bleeding events in contemporary VAD 
patients.  
4.2 PATIENTS AND METHODS 
4.2.1 Patient selection and devices 
The University of Pittsburgh’s Institutional Review Board (IRB) approved all study procedures 
and consent forms for data collection, blood collection and data analysis for this investigation. 
Written consent for this study was obtained from all participants. 
This study was a single-center investigation which consisted of patients who underwent 
placement of a long-term LVAD (intended length of support >14 d) at the University of 
Pittsburgh Medical Center (UPMC) Presbyterian Hospital between January 2001 and November 
2011. Patients were excluded if they were implanted with a temporary LVAD, implanted with a 
long-term right ventricular assist device, or were supported less than 2 months with the device. 
Three different devices were included in this study: the Thoratec® HeartMate II® (HMII; 
Thoratec; N=31) and HeartWare® HVAD ® (HW; HeartWare Inc, Framingham, MA; N=15) 
rotary blood pumps, and the Thoratec® PVAD™ pneumatic device (PVAD; Thoratec Corp, 
Pleasanton, CA; N=17). Medical history, post-operative complications and laboratory test values 
were collected from the IRB-approved Transplant Patient Management System database at 
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UPMC. MELD score was calculated within 5 days of implantation by previously described 
methods.[143,145] Interagency Registry of Mechanically Assisted Circulatory Support 
(INTERMACS) definitions were used to determine the occurrence of bleeding adverse events.[9] 
Similar to a report by Goldstein et al, neurological deficits (i.e. transient ischemic attacks, 
cerebrovascular accidents) suspected to be caused by emboli and thromboectomy procedures 
were combined into the thromboembolism adverse events category.[7] A subset of patients 
(N=21) were included in an investigation of circulating sub-clinical biomarkers of hemostasis 
and consented to providing blood samples throughout device support. 
All patients followed the same anticoagulation guidelines. Surgical implantation was 
performed with cardio-pulmonary bypass (CPB) using systemic anticoagulation with heparin 
(target partial thromboplastin time (PTT) >480 s). Protamine was administered following CPB 
wean for full anticoagulation reversal. The sternum was closed unless there were indications of 
possible right ventricular dysfunction. Normal hemostasis was encouraged in the early post-
operative period. Following a reduction in chest tube drainage, patients were anticoagulated with 
heparin (target PTT = 1.5 to 2.5 times institutional normal) as a bridge to Warfarin therapy. Per 
clinical discretion, 81 mg aspirin was administered daily and increased to 325 mg through 
thrombelastography monitoring (target platelet arachidonic acid inhibition >70%). Warfarin was 
initiated within 7 days of surgery, with a target INR that was determined by device used (target 
INR vaules: HMII = 2.2 - 2.8, HW = 2.5 - 3.0, PVAD = 2.5 - 3.5). 
4.2.2 Determination of biomarker activation levels 
Circulating levels of activated platelets and platelet-platelet microaggregates were measured 
using previously established protocols.[147,148] Briefly, whole blood was added to Dulbecco's 
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phosphate-buffered saline without Ca++ or Mg++ (DPBS; MP Biomedicals LLC, Solon, OH) 
with appropriate concentrations of recombinant phycoerythrin-conjugated mouse anti-human 
CD42b (Abd Serotec, Raleigh, NC), and either PE-CyTM5-conjugated mouse anti-human CD62P 
(p-selectin) or matched isotype control (both from BD, San Diego, CA) and incubated in the dark 
for 20 min. The cells were washed with DPBS, centrifuged, and the pellet isolated. The cells 
were re-suspended in 1% paraformaldehyde and stored at 4°C (<24 hr) until analyzed. CD42b+ 
events (>5000) were collected on a 3-color FACScan (BD) and analyzed with WINList software 
(Verity Software House, Topsham, ME). Flow cytometry size calibration beads (3.4 µm 
diameter, Spherotec Inc., Lake Forrest, IL) were analyzed weekly to provide the basis for 
distinguishing single platelets from platelet microaggregates. Single platelets expressing p-
selectin were defined as appropriately sized CD42b+ cells exhibiting anti-CD62P binding higher 
than 98% of isotype control. Platelet-platelet microaggregates were defined as being larger than 
single platelets and exhibiting simultaneous increase in CD42b expression and forward scatter 
intensity. The percentages of p-selectin positive single platelets and platelet-platelet 
microaggregates were combined to produce the index of total circulating platelet activation. 
Plasma levels of D-dimer and prothrombin fragment F1+2 (F1+2) were determined using 
commercially available enzyme linked immunosorbent assays according to the manufacturer’s 
instructions (D-dimer: American Diagnostica, Stamford, CT; F1+2: Siemens Healthcare 
Diagnostics, Deerfield, IL).  
4.2.3 Statistical analyses 
All values are presented as mean and standard error of the mean (SEM) unless specified. Pre-
operative patient characteristics were analyzed using ANOVA with Bonferroni post hoc tests for 
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normally distributed continuous data, Mann-Whitney non-parametric tests for ordinal or non-
normally distributed data and Chi-square (using the Likelihood Ratio statistic) analyses for 
categorical data. Temporal studies were analyzed by repeated measures ANOVA with 
Bonferroni post hoc testing between variables. Univariate linear regression analysis was used to 
investigate the utility of MELD scores to predict peri-operative blood product consumption, 
chest tube drainage and cardio-pulmonary bypass (CPB) time. Univariate linear regression was 
also performed with several pre-operative variables for the prediction of post-operative total 
blood product consumption. Variables that predicted total blood product consumption with 
P<0.25 were included in a multivariate linear regression. Step-wise backward linear regression 
was used, with entry and exit criterion set at P<0.25 and P<0.05, respectively. Statistical 
significance was assumed at P<0.05 for all tests. All statistics were performed with SPSS v16.0 
(IBM Corp, Armonk, NY).  
 
4.3 RESULTS 
4.3.1 Patient demographics 
A total of 63 patients were followed for the first two months of VAD support. PVAD patients 
were significantly younger than the other two devices (P=0.002) and had a lower body surface 
area (P=0.034) (Table 4.A). The overall average MELD score of this study was 14.9 ± 0.1, 
which is similar to other reports.[144,146] There were no significant differences in mean MELD 
scores between type of LVAD (mean ± standard error of the mean: HMII=15.1 ± 0.9, HW=13.0 
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± 1.0, PVAD=15.7 ± 1.4) (P=0.34). Following the methodology of similar investigations which 
utilized quartiles to separate patients into high and low MELD score cohorts, the patients in this 
study were separated a priori by the 75% quartile, resulting in a cut-point of 18.0.[143,145] 
Patients with a MELD score above the 75% quartile (high MELD group) were significantly more 
likely to have been supported pre-operatively with an intra-aortic balloon pump (P=0.019) 
(Table 4.A). There was a similar distribution of devices between the high MELD score cohort 
(HMII=10, HW=2, PVAD=4) and the low MELD cohort (HMII=21, HW=13, PVAD=13) 
(P=0.418). 
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Table 4.A: MELD Score patient demographics and heart failure information 
Demographics
Implant Age (yr) 56 ± 14 57 ± 16 42 ± 14 a 57 ± 14 51 ± 16
Sex (% male) 84 % 67 % 53 % 88 % 66 %
Survive to Transplant/Explant 74 % 67 % 88 % 75 % 77 %
Diabetes % 32 % 53 % 18 % 38 % 32 %
Smoker % 68 % 67 % 65 % 75 % 64 %
Pre-op Hemodynamics
BSA (m2) 2.1 ± 0.3 1.9 ± 0.3 1.8 ± 0.2 b 2.0 ± 0.3 1.9 ± 0.3
CO (L/min) 4.3 ± 1.1 4.4 ± 1.6 3.9 ± 1.3 4.1 ± 1.4 4.2 ± 1.3
CI (L/min/m2) 2.1 ± 0.5 2.2 ± 0.7 2.1 ± 0.6 2.0 ± 0.6 2.1 ± 0.6
LVEF % 14 ± 5 18 ± 7 15 ± 5 15 ± 6 15 ± 6
BP Mean 85 ± 11 77 ± 11 77 ± 8 c 84 ± 12 80 ± 11
PAP Mean 37 ± 10 38 ± 9 38 ± 11 39 ± 9 37 ± 10
CVP 11 ± 7 13 ± 5 15 ± 7 14 ± 6 12 ± 7
Pre-op Support
Milrinone (mg) 0.5 ± 0.9 0.4 ± 0.2 0.3 ± 0.2 0.4 ± 0.2 0.4 ± 0.7
IABP % 52 % 33 % 53 % 75 % 38 % d
IABP (avg days) 4.7 ± 2.0 4.0 ± 1.9 4.1 ± 2.5 4 ± 2 4 ± 2
ECMO % 3 % 0 % 6 % 6 % 2 %
ECMO (days) 5 0 6 5 6
Pre-operative Diagnosis
Ischemic 48 % 33 % 41 % 38 % 45 %
Non-ischemic 45 % 47 % 41 % 56 % 43 %
Other 6 % 20 % 18 % 6 % 13 %
Concomitant Support
RVAD % 16 % 20 % 29 % 19 % 21 %
RVAD (avg days) 14 ± 10 9 ± 4 7 ± 3 7 ± 2 11 ± 8
Average ± Standard Deviation where applicable
a: HMII vs HW P>0.99 , HMII vs PVAD P =0.004, HW vs PVAD P =0.011.
b: HMII vs HW P =0.29, HMII vs PVAD P =0.032, HW vs PVAD P>0.99 .
c: HMII vs HW P =0.085, HMII vs PVAD P =0.041, HW vs PVAD P>0.99 .
d: P =0.019
BP=Blood Pressure     BSA=Body Surface Area     CI=Cardiac Index     CO=Cardiac Output     CVP=Central Venous Pressure
DT=Destination Therapy     ECMO=Extracorporeal Membrane Oxygenation     HMII=HeartMate II     HW=HeartWare
IABP=Intra-Aortic Balloon Pump     LVEF=Left Ventricular Ejection Fraction     PAP=Pulmonary Artery Pressure
PVAD=Thoratec PVAD pneumatic     RVAD=Right Ventricular Assist Device
         
Device Group MELD Cut-point Group
HMII (N=31) HW (N=15) PVAD (N=17) >18.0 (N=16) <18.0 (N=47)
 
 
A subset of 21 patients had biomarker studies performed (HMII = 10, HW = 7, PVAD = 
4). In this subset, the PVAD patients were significantly more likely to have a temporary RVAD 
placed during implantation (PVAD N=3, HMII N=1, HW N=1) (P=0.048) than the other pumps, 
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but the duration of RVAD support if needed was similar to that found in the other pumps 
(PVAD=7±1.7 vs. HMII=5 and HW=6 d). The same MELD threshold of 18.0 was applied to this 
subset; the resultant high MELD score cohort consisted of 7 patients (HMII=5, HW=1 and 
PVAD=1) and the low MELD score cohort consisted of 14 patients (HMII=5, HW=6, PVAD=3). 
There were no other significant pre-operative differences between the high and low MELD score 
subset groups (Table 4.B). 
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Table 4.B: MELD score subgroup patient demographics and heart failure information 
Demographics
Implant Age (yr) 52 ± 15 51 ± 18 37 ± 15 56 ± 13 45 ± 17
Sex (% male) 80 % 86 % 25 % 100 % 43 %
Survive to Transplant/Explant 70 % 57 % 100 % 57 % 79 %
Diabetes % 30 % 29 % 0 % 43 % 14 %
Smoker % 70 % 57 % 75 % 71 % 64 %
Hemodynamics
BSA (m2) 2.2 ± 0.4 2.0 ± 0.3 1.8 ± 0.1 2.1 ± 0.4 2.0 ± 0.4
CO (L/min) 4.4 ± 1.2 5.0 ± 2.2 4.2 ± 1.6 4.8 ± 1.6 4.4 ± 1.6
CI (L/min/m2) 2.0 ± 0.4 2.5 ± 0.8 2.4 ± 0.7 2.3 ± 0.5 2.2 ± 0.7
LVEF % 14 ± 6 19 ± 7 16 ± 6 16 ± 7 16 ± 7
BP Mean 80 ± 11 77 ± 13 76 ± 9 81 ± 10 77 ± 12
PAP Mean 34 ± 6 39 ± 10 34 ± 10 34 ± 6 37 ± 9
CVP 9 ± 5 15 ± 6 14 ± 4 11 ± 5 12 ± 5
Pre-op Support
Milrinone (mg) 0.3 ± 0.2 0.5 ± 0.2 0.4 ± 0.1 0.3 ± 0.2 0.4 ± 0.2
IABP % 50 % 57 % 50 % 71 % 43 %
IABP (avg days) 5.3 ± 3.0 3.8 ± 2.1 4.5 ± 0.7 4.0 ± 3.0 4.8 ± 2.2
ECMO % 10 % 0 % 0 % 14 % 0 %
ECMO (days) 5 0 0 5 0
Concomitant Support
RVAD % 10 % 14 % 75 % a 14 % 29 %
RVAD (avg days) 5 6 7 ± 1.7 5 7 ± 1.7
Pre-operative Diagnosis
Dilated Myopathy: Idiopathic 50 % 0 % 25 % 29 % 29 %
Dilated Myopathy: Ischemic 40 % 57 % 25 % 43 % 43 %
Dilated Myopathy: Adriamycin 0 % 14 % 0 % 0 % 7 %
Dilated Myopathy: Postpartum 0 % 14 % 0 % 0 % 7 %
Dilated Myopathy: Other 0 % 0 % 25 % 0 % 7 %
Myocardial Infarction 10 % 0 % 0 % 14 % 0 %
Congestive Heart Failure 0 % 14 % 0 % 14 % 0 %
Chemotherapy Induced 0 % 0 % 25 % 0 % 7 %
Average ± Standard Deviation where applicable *  P<0.05
a: HMII vs HW P>0.99 , HMII vs PVAD P=0.041 , HW vs PVAD P=0.088 .
BP=Blood Pressure     BSA=Body Surface Area     CI=Cardiac Index     CO=Cardiac Output     CVP=Central Venous Pressure
DT=Destination Therapy     ECMO=Extracorporeal Membrane Oxygenation     HMII=HeartMate II     HW=HeartWare
IABP=Intra-Aortic Balloon Pump     LVEF=Left Ventricular Ejection Fraction     PAP=Pulmonary Artery Pressure
PVAD=Thoratec PVAD pneumatic     RVAD=Right Ventricular Assist Device
<18.0 (N=14)
      
Device Biomarkers Group MELD Biomarkers Group
HMII (N=10) HW (N=7) PVAD (N=4) >18.0 (N=7)
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4.3.2 Blood product transfusion and bleeding adverse events 
Blood products transfused within the first 48 h post-implant, chest tube drainage within the first 
24 h post-implant and CPB time during the implant surgery were each regressed on MELD 
score, resulting in a significant positive relationship for each variable tested (Table 4.C, Figure 
4.1).  
 
Table 4.C: Peri-operative outcomes regressed onto MELD score (N=63) 
Peri-Operative Outcomes R R2 P Coefficient β Standard Error β
Total Blood Products (Units) 0.37 0.13 0.003 1.02 0.33
Packed Red Blood Cells (Units) 0.30 0.07 0.018 0.21 0.09
Packed Platelets (Units) 0.41 0.15 0.001 0.50 0.14
Cryoprecipitate (Units) 0.20 0.02 0.121 0.06 0.04
Fresh Frozen Plasma (Units) 0.26 0.05 0.043 0.25 0.12
Chest Tube Drainage per 48 h (mL) 0.28 0.06 0.026 70.75 30.92
Cardiopulmonary Bypass Time (min) 0.25 0.05 0.048 1.85 0.92  
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Figure 4.1: Linear regression example for total blood products regressed onto MELD score (N=63). 
 
Predictors of total blood product usage (TBPU) during the first 48 h of VAD support 
were first analyzed by univariate linear regression analysis (Table 4.D). Variables having P > 
0.25 were then entered into a multivariate linear regression analysis (Table 4.E). Contributors to 
the final model were MELD score, age, mean pulmonary artery pressure and body surface area, 
with MELD score (P = 0.004; standardized β = 0.35) and age (P = 0.016; standardized β = 0.28) 
exhibiting the strongest predictive value.  
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Table 4.D: Pre-operative univariate predictors in VAD patients of peri-operative total blood product 
requirements (N=63) 
R R^2 P
Age (yr) 0.357 0.128 0.004
MELD Score 0.321 0.103 0.010
Body Surface Area (mm3) 0.223 0.050 0.078
Left Ventricular Ejection Fraction (%) 0.166 0.027 0.195
Mean Pulmonary Artery Pressure (mmHg) 0.160 0.026 0.210
Platelet Count (x109/dL) 0.149 0.022 0.244
Sex 0.143 0.020 0.264
Cardiac Index 0.073 0.005 0.572
Central Venous Pressure (mmHg) 0.070 0.005 0.587
Pre-operative ECMO Support 0.070 0.005 0.588
Pre-operative IABP Support 0.054 0.003 0.674
Smoker 0.035 0.001 0.786
Mean Blood Pressure (mmHg) 0.021 0.001 0.873
Diabetes 0.004 0.001 0.975  
 
Table 4.E: Multivariate predictors of total blood product requirements post-VAD implantation* 
P Coefficient β Standard Error β Standardized  β
MELD Score 0.004 0.98 0.32 0.35
Age (yr) 0.016 0.25 0.10 0.28
Mean Pulmonary Artery Pressure (mmHg) 0.095 -0.29 0.17 -0.20
Body Surface Area (mm3) 0.107 -8.99 5.50 -0.19
Left Ventricular Ejection Fraction (%) 0.442
Platelet Count (x109/dL) 0.931
*Final Model Statistics: R = 0.54, R2 = 0.29, P = 0.001  
 
When patients were grouped by high and low MELD scores, the high MELD patients had 
significantly higher TBPU, packed red blood cell (PRBC) units, and packed platelet units during 
the first 48 h post-implantation. The high MELD group also and had more chest tube drainage 
during the first 24 h of support (Table 4.F).  
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Table 4.F: Differences in intra- and peri-operative variables by MELD score cut-point 
Mean SEM Mean SEM P Mean SEM
Chest Tube Drainage (24hr) 2583 429 1607 146 0.045 1855 161
Total Blood Products (Units) 21 4 10 2 0.021 13 2
Red Blood Cells (Units) 5 1 3 0 0.050 4 1
Packed Platelets (Units) 8 2 3 1 0.015 4 1
Cryoprecipitate (Units) 1 0 1 0 0.135 1 0
Fresh Frozen Plasma (ml) 7 2 3 1 0.078 4 1
CPB Time (min) 123 11 106 5 0.118 110 5
CPB = Cardio-pulmonary Bypass; SEM = Standard Error of the Mean
MELD > 18.0 MELD < 18.0 All Patients
(N=63)(N=16) (N=47)
 
 
VAD patients with high pre-operative MELD scores exhibited significantly lower platelet 
counts to post-operative day (POD) 55 than patients with low MELD scores (P = 0.006, Figure 
4.2). All patients had a drop in platelet count at POD 2 (P<0.001) which then recovered and were 
then above pre-operative levels by POD 12 (Figure 4.2). Though the high MELD score patients 
had lower pre-operative platelet counts compared to low MELD patients (150 ± 18 vs. 191 ± 9 
x109/dL), this difference became much more pronounced at POD 6 and continued to POD 26 
(with differences of 88, 73 and 52 x109/dL for POD 6, POD 12 and POD 26, respectively).  
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 Figure 4.2: Temporal differences in platelet counts between VAD patients with high and low pre-operative 
MELD scores. Data are presented as mean plus standard error of the mean. The “0” on the abscissa indicates 
preoperative values. MELD, Model for End-stage Liver Disease. 
 
Although the rates of bleeding and thromboembolism for the high MELD patients were 
consistently higher than those found in the low MELD groups, this difference was not 
statistically significant for the time-periods examined. However, the percentage of patients that 
experienced at least one bleeding event over the course of the study was significantly higher in 
the high MELD group than the low MELD group (High MELD: 13 of 16 patients vs. Low 
MELD: 24 of 47, P=0.043; Table 4.G). 
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Table 4.G: Unique adverse events experienced by an implanted patient per patient-day of support 
Implant to 
POD 2
POD 3 to 
POD 30
POD 31 to 
POD 60
Event 
Experienced*
Implant to 
POD 2
POD 3 to 
POD 30
POD 31 to 
POD 60
Event 
Experienced*
MELD > 18 (N=16) 0.344 0.049 0.015 81% 0.031 0.007 0.000 19%
MELD < 18 (N=47) 0.223 0.017 0.004 51% 0.011 0.004 0.002 17%
P 0.268 0.211 >0.999 0.043 >0.999 0.762 0.564 >0.999
*The precentage of patients that experienced the indicated adverse event at least once during the first 60 days of support
Bleeding Thromboembolic
 
4.3.3 Circulating hemostatic biomarkers 
High and low MELD score patients had significantly different plasma F1+2 concentration trends 
with respect to time over the length of the study (P=0.033, Figure 4.3 A). While F1+2 
concentrations in the high MELD score patients were typically higher than the low MELD 
patients (P=0.010 at POD 2), the high MELD patients briefly dropped below the levels found in 
the low MELD patients on PODs 6 and 12 before returning to elevated levels for the remainder 
of the study. High and low MELD score patients also exhibited plasma F1+2 levels elevated far 
above the manufacturer’s suggested normal median value of 115 pmol/L  (95th percentile = 229 
pmol/L) throughout the study (Figure 4.3 A).  
Patients with high MELD scores had a greater degree of circulating platelet activation 
throughout the study but was only significantly elevated above low MELD score patients on 
POD 6 (P=0.001, Figure 4.3 B). Patients in the high and low MELD score groups exhibited 
similar trends regarding plasma D-dimer levels, with a significant drop immediately following 
VAD implantation (P<0.035), followed by a significant rise over pre-operative levels to POD 26 
(P<0.010, Figure 4.3 C). Though both groups of patients had very similar post-operative D-
dimer levels to POD 26, patients with high MELD scores had significantly higher elevations of 
D-dimer at POD 55 while low MELD score patients dropped to near pre-operative values. D-
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dimer levels in both groups of patients were substantially elevated over the manufacturer’s 
suggested normal concentration of <400 ng/mL, with the lowest concentration being 1607 ng/mL 
by the low MELD group on POD 2. 
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 Figure 4.3: Temporal differences in circulating sub-clinical thrombosis markers between VAD patients with 
high and low pre-operative MELD scores as measured by: (A) Plasma concentration of prothrombin 
fragment F1+2. (B) Percent of circulating platelets expressing P-selectin or involved in microaggregates. (C) 
Plasma concentration of D-dimer. Data presented as mean plus standard error of the mean. The “0” on the 
abscissa indicates preoperative values. MELD, Model for End-stage Liver Disease. 
 78 
4.3.4 Differences in circulating hemostatic markers between devices 
There were no differences between the 3 devices for F1+2 or circulating platelet activation at any 
timepoint examined (Figure 4.4 A, B). When stratified by type of VAD implanted, each VAD 
patient cohort exhibited circulating D-dimer trends similar to the high and low MELD 
comparison (Figure 4.3 C vs Figure 4.4 C). All 3 VAD groups have similar concentrations of 
D-dimer to POD 14, but the HMII patients remained significantly elevated over the PVAD and 
HW patients on POD 26 (7943 vs. 6096 and 4984, respectively) and POD 55 (5391 vs. 2748 and 
1944, respectively; Figure 4.4 C).  
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 Figure 4.4: Temporal differences in circulating sub-clinical thrombosis markers between VAD patients 
separated by device implanted as measured by: (A) Plasma concentration of prothrombin fragment F1+2. (B) 
Percent of circulating platelets expressing P-selectin or involved in microaggregates. (C) Plasma 
concentration of D-dimer. Data presented as mean plus standard error of the mean. The “0” on the abscissa 
indicates preoperative values. HMII, HeartMate II; HW, HeartWare; PVAD, Thoratec pneumatic VAD. 
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When patients were separated by type of LVAD implanted (regardless of MELD score), 
no significant differences were found between the 3 VADs regarding chest tube drainage or 
blood product consumption. However, the PVAD cohort had a significantly longer duration of 
intra-operative bypass than either the HMII or the HW patients (P=0.010, Table 4.H). 
 
Table 4.H: Differences in intra- and peri-opeative variables by device implanted 
Mean SEM Mean SEM Mean SEM P
Chest Tube Drainage (24hr) 2079 255 1578 311 1689 254 0.387
Total Blood Products (Units) 13 3 11 3 13 2 0.877
Red Blood Cells (Units) 4 1 4 1 4 1 0.959
Packed Platelets (Units) 5 1 3 1 4 1 0.665
Cryoprecipitate (Units) 1 0 1 1 1 0 0.988
Fresh Frozen Plasma (ml) 5 1 4 1 4 1 0.843
CPB Time (min) 101 3 103 11 133 12 0.010
CPB = Cardio-pulmonary Bypass; SEM = Standard Error of the Mean
(N=31) (N=15) (N=17)
HMII HW PVAD
 
4.4 DISCUSSION 
Pre-operative prediction of hemostatic complications following VAD implantation would be of 
great benefit in enabling physicians to more effectively manage patients in the peri-operative and 
early post-operative periods. Previous studies suggest that VAD patients are most at risk for 
bleeding and thromboembolic events during the first 30 days of support, with a concomitant 
increased risk of 1 year morbidity and mortality.[6,24,142] Administration of blood products has 
been associated with increased allosensitization of VAD patients, increasing transplant waiting 
periods and risk of post-transplant cellular rejection.[119] 
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The MELD score was originally developed as a predictor of mortality and morbidity in 
patients undergoing transjugular, intrahepatic portosystemic shunts, and has since been utilized 
in a similar manner for general non-cardiac and cardiac surgeries, including VAD 
implantation.[144,149-153] While other studies have shown the utility of MELD scores to 
predict post-operative bleeding, the relationship between high pre-operative MELD scores and 
increased bleeding is not completely understood. Some have speculated that plasma coagulation 
proteins may become imbalanced from cardiac hepatopathy due to congestion from right 
ventricular failure as well as poor hepatic perfusion from left ventricular failure.[146,154]  
Recently, MELD scores have been positively correlated with peri-operative bleeding and 
blood product consumption. Matthews et al found that pre-operative MELD score significantly 
predicted TBPU as well as individual product components such as RBCs, platelets, plasma and 
cryoprecipitate.[143] Matthews also found MELD score to be a significant predictor of TPBU in 
multivariate analysis. However, 80% of the 211 VAD patients analyzed in the study were 
implanted with now-obsolete pumps. Similarly, Deo et al reported a positive correlation with 
pre-operative MELD score and both TBPU and platelets in 126 HMII patients.[145] Deo also 
found a positive correlation between pre-operative MELD score and TBPU in first-time cardiac 
surgery VAD patients but not in re-operative cardiac surgery VAD patients. 
Our study confirmed these reports and expanded upon them by the inclusion of several 
current devices in the patient selection and the addition of chest tube drainage and CPB time as 
peri-operative variables. All blood products examined had a significant, positive correlation to 
pre-operative MELD score except cryoprecipitate (Table 4.C). None of the correlations were 
especially strong, and were similar to those found by Matthews et al.[143] Peri-operative chest 
tube drainage and CPB time were also significantly correlated to pre-operative MELD score 
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(Table 4.C). Separation into high and low MELD score cohorts by 75% quartile yielded similar 
results except for cryoprecipitate, plasma and CPB time (Table 4.F). Not surprisingly, a 
significantly larger percentage of the high MELD cohort experienced at least one bleeding 
adverse event during the first 60 days of support (Table 4.G). When multivariate linear 
regression analysis was performed on TPBU, MELD score was a significant predictor along with 
age and mean pulmonary artery pressure (Table 4.E). A recent report by Solomon et al suggests 
that perioperative administration of fibrinogen concentrate can reduce transfusions during 
thoracic surgery.[155] The low concentration of fibrinogen in cryoprecipitate may have 
contributed to cryoprecipitate’s relatively reduced administration in these patients. Utilization of 
fibrinogen concentrate may prove to be useful in high MELD score patients.  
Hemostatic monitoring of VAD patients in the immediate post-operative period continues 
to be challenging. Underlying hemostatic problems may not be apparent until challenged by 
major cardiothoracic surgery procedures. Previous studies have shown the utility of circulating 
hemostatic markers such as F1+2 and D-dimer to be sensitive indicators of sub-clinical 
hemostatic imbalance.[5,48,50,156] The temporal trends of F1+2 and D-dimer in the low MELD 
score group in this study were similar to trends reported by Wagner et al and the post-operative 
time course of platelet counts in the low MELD score group were similar to a study by John et 
al.[5,156] However, the high MELD score patients had a different post-operative F1+2 trend 
than the low MELD score patients, with significantly higher levels on POD 2 (Figure 4.3 A). 
Differences in circulating D-dimer levels between the two groups also became significant later in 
the implant period, as the high MELD score patients experienced elevated levels on POD 55 
(Figure 4.3 C). Furthermore, among the larger population of patients in this study, the high 
MELD score group exhibited a significantly different temporal trend of platelet counts than the 
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low MELD group, with lower platelet counts for the first month of VAD support (Figure 
4.2).[156] High MELD score patients exhibited increased thrombin generation in the early post-
operative period, and decreased platelet counts and prolonged fibrinolysis during recovery. 
Differences in device hemodynamics or surgical procedure might not sufficiently explain the 
differences found in this study as the three VAD types were evenly distributed among the low 
and high MELD groups. Instead, the patient’s pre-operative condition may have a persistent 
influence on sub-clinical hemostasis, though the manifestation of this influence is still to be 
determined. 
In this study the type of VAD implanted was not a significant factor in any of the peri-
operative bleeding measurements despite very different surgical implantation techniques and 
VAD hemodynamic profiles. The PVAD required a significantly longer period of time on CPB 
than either the HMII or the HW, which may reflect the PVAD requirement of tunneling an extra 
cannula through the skin. Neither the presence of two large exit sites for the PVAD nor the sub-
diaphragm pump pocket of the HMII were associated with increased blood product usage or 
chest tube output (Table 4.H). Patients on all 3 devices had similar temporal F1+2, circulating 
platelet activation and D-dimer responses, which were greatly increased over the reported normal 
ranges for all time points, and were similar to other reports on VAD patients (Figure 
4.4).[5,48,156] D-dimer concentrations in HMII patients became significantly higher at 1 and 2 
months, which may reflect ongoing fibrinolysis at the textured inflow cannula, which is unique 
to this pump (Figure 4.4 C). 
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4.5 LIMITATIONS 
This was a single institution study consisting of a relatively small number of patients; a larger 
multi-center study is warranted. The methodology of this study focused on assessing the 
immediate and prolonged effect of pre-operative MELD scores on hemostasis in VAD patients. 
Only patients that were supported for at least 55 days post-operatively were included in the 
study, which may result in some selection bias. However, recent INTERMACs data suggest this 
still represents >90% of all VAD patients implanted.[6] This bias also prevented mortality 
prediction with MELD scores, as the results would have been skewed, although this association 
has already been extensively reported. Additionally, only patients implanted during the last 2 
years of the study were followed for investigation of biomarkers of hemostasis, which could 
contribute to a bias towards healthier patients due to better patient management from increased 
institutional experience. However, this effect should be limited as all biomarker patients were 
enrolled during the same period, limiting differences between eras in surgical techniques and 
patient management. Inclusion of the pulsatile PVAD could be a limitation due to differences in 
flow patterns and wall shear stresses compared to the rotary HMII and HW. However, part of 
this study was designed as an assessment of bleeding outcomes and hemostatic markers between 
pulsatile and rotary VADs. The combination of this evaluation of the three devices with an 
investigation of the influence of pre-operative liver dysfunction revealed that liver dysfunction 
strongly affected hemostasis for several weeks after implantation, while the type of VAD had 
little impact. This does not suggest that VAD design is negligible, and the authors suspect that 
differences in VAD design may have an increased influence on bleeding and thrombosis further 
from the time of implantation. However, this was not investigated. At the time of enrollment for 
this study, implantation of the HW VAD was governed by a clinical trial protocol that may have 
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biased patients towards a healthier pre-operative condition, yet this bias was not apparent in pre-
operative patient characteristics (Tables 4.A and 4.B), nor in the pre-operative measurement of 
any of the indices included in this study.[157] Given that this study was the first attempt at this 
institution to carefully review the relationship between MELD score and post-operative 
hemostasis, there was no evidence-based algorithm to treat factors based upon the MELD score. 
As more contributions to this area of research are provided, an investigation of an evidence-
based algorithm may be warranted. 
4.6 CONCLUSION 
Pre-operative hepatic and renal dysfunction appears to have immediate and long lasting 
hemostatic effects on VAD patients. MELD score was a predictor of post operative blood 
product administration, chest tube drainage and bleeding adverse events regardless of the VAD 
implanted. VAD patients with high pre-operative MELD scores exhibited significantly different 
temporal trends of thrombin generation and platelet counts, as well as protracted fibrinolysis. 
Though the rate of adverse events decreased markedly after the first 2 days of implantation, the 
sub-clinical effects of a high pre-operative MELD score on the hemostatic system appeared to be 
persistent. 
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5.0  REAL TIME VISUALIZATION OF PLATELET DEPOSITION UNDER FLOW 
ONTO CLINICALLY-RELEVANT OPAQUE SURFACES 
5.1 INTRODUCTION 
Many cardiovascular devices such as vascular grafts, stents, and heart valves are susceptible to 
the risk of device thrombosis and thromboembolic events.[158] A large portion of biomaterial 
research has been devoted to investigating materials to reduce the thrombogenicity of cardiac 
devices. Materials such as poly(ethylene glycol) (PEG), biomimetic phosphorylcholine-based 
surfaces, sulfobetaines, covalently bonded albumin and functional heparin-immobilized materials 
have been studied extensively as coatings for blood contacting devices to reduce platelet 
adhesion. Deible et al effectively masked the thrombogenic surface of denuded human placental 
arteries by covalently attaching PEG-diisocyanate to the exposed surface proteins.[159] The 
coated arteries had decreased platelet deposition compared to similar arteries exposed to a non-
reactive PEG solution. Ye et al reported on the reduction of platelet deposition and bulk-phase 
platelet activation of silinated 2- methacryloyloxyethyl phosphorylcholine (MPC)- or 
sulfobetaine - coated TiAl6V4 compared to uncoated TiAl6V4.[88] Eberhart et al immobilized 
albumin through the addition of alkyl groups onto 4 and 5 mm polyetherpolyurethane tubes.[160] 
The coated tubes showed less thrombogenicity in a canine vascular graft model than non-coated 
tubes. An oft-used technique for covalent heparin immobilization is the end-point immobilization 
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method, in which a reactive aldehyde group is exposed on the heparin chain and conjugated to a 
primary amine on the substrate. This technique was used by Lin et al on a 
polytetrafluoroethylene small diameter graft and evaluated for platelet deposition and graft 
patency using a baboon femoral artery graft model.[161] Reduced platelet deposition was found 
on the coated grafts compared to uncoated at 1 and 4 hrs post implant, and coated graft patency 
was improved at 4 wks compared to the uncoated grafts. 
As described in Section 1.1, among long-term cardiovascular devices, continuous flow 
VADs are particularly difficult to reduce the risk of thrombosis and thromboembolism due to a 
combination of fluid dynamics, length of expected support, patient population and small blood 
volume to surface area ratio.  
While the importance of patient selection and pre-operative risk factors continues to be 
studied (Chapter 4), these investigations are most likely to affect post-operative medical 
management of anticoagulation. Moreover, consistent anticoagulation has shown to be difficult 
even in patients without the thrombogenic environment of mechanical circulatory 
support.[4,10,49] In light of these difficulties, the optimization of the blood contacting material 
in the pump is an area where small improvements could greatly enhance the biocompatibility 
performance of VADs.  However, A remarkable number of VAD developers use highly polished 
TiAl6V4 (e.g. Heartmate II, Jarvik 2000, HeartWare HVAD) as the blood – contacting material 
despite only moderate hemocompatibility.[82,83,162,163]  
A method for accessing time dependent, flow induced platelet adhesion and thrombosis 
formation on clinically relevant surfaces could improve material evaluation of VADs during 
design and improve material selection. Since opaque materials are often used in VADs, 
traditional methods for real time platelet deposition are not applicable. A method for real time 
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visualization and characterization of platelet deposition onto opaque materials under 
physiologically–relevant conditions was developed. This was accomplished through the use of a 
parallel plate flow chamber perfused with a whole blood analog of fluorescently labeled donor 
platelets with transparent hemoglobin–depleted red blood cells (RBC ghosts) and observed with 
long working distance epifluorescence microscopy.  Real-time platelet deposition onto polished 
TiAl6V4 along with several alternative continuous flow VAD materials was then observed and 
recorded using this novel approach. 
5.2 MATERIALS AND METHODS 
5.2.1 Platelet collection and fluorescent labeling   
Fresh whole blood was collected from healthy donors who had refrained from taking any anti-
platelet agents 14 days prior to collection. Platelet-rich-plasma (PRP) was collected by 
centrifuging citrated blood (0.5 mL Vacutainer tubes, [0.105M] citrate, BD, Franklin Lakes, NJ, 
USA) at 250xg for 15 min. Platelets were fluorescently labeled by the addition of quinacrine 
dihydrochloride (0.5 μM final concentration, Sigma-Aldrich, St. Louis, MO, USA) to the PRP. 
5.2.2 RBC ghost cell preparation and characterization 
Units of packed RBCs (type O-, Valley Biomedical Products & Services, Inc., Winchester, VA, 
USA) were converted into RBC ghosts through the modification of established protocols.[164-
167] Briefly, the RBCs were rinsed and centrifuged (2000xg, 15 min) three times with phosphate 
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buffered saline without Ca2+ or Mg2+ (PBS, VWR International LLC., Radnor, PA, USA) and 
then suspended in PBS at a 50% hematocrit. On ice, the RBC suspension was added 1:10 to a 
lysing solution composed of 4mM MgSO4, 5X concentrated PBS, and acetic acid (Sigma-
Aldrich Co. LLC.) in distilled water with a final osmolality of 40 mOsm and pH of 5.0-5.2. After 
5 min, osmolality and pH were increased to physiologic norms (300 mOsm and 7.8, respectively) 
by the addition of 0.3 mL of 5X concentrated PBS and 2µL of 1M Tris buffer (Thermo Fisher 
Scientific Inc., Pittsburgh, PA, USA ) per mL of cell suspension and incubated on ice for 8 hrs. 
The cells were then resealed by incubation at 37°C for 1 hr. The suspension was centrifuged at 
25400xg for 30 min and the supernatant was discarded. The cells were washed 3 times with PBS 
(25400xg for 30 min) and stored in PBS with 1 mL/L gentamicin (Thermo Fisher Scientific). 
The resultant RBC ghosts were observed to be translucent.  
Prior to RBC ghost cell creation, an aliquot of native RBCs was set aside for comparative 
rheological testing. The viscosity of RBC ghosts in human plasma was measured using a cone 
and plate viscometer (Brookfield Digital Rheometer, Model DV-III, Brookfield Engineering 
Laboratories, Inc., Stoughton, MA, USA) and compared to native RBCs. The elongation index 
under various wall shear rates for RBC ghosts and native RBCs was measured using a CSS 
Optical Rheology System (Linkam Scientific Instruments Ltd., Tadworth, Surrey, UK) and 
analyzed using ImageJ imaging software (NIH). The elongation index was calculated as 
(L−W)/(L+W) where L and W are the major and minor axes of the ellipse, respectively.  
Additionally, the translucence of the RBC ghosts was verified by replacing the test 
material on the parallel plate flow chamber with a microscope slide that was pre-loaded with 
immobilized 5.5 µm beads that fluoresce at the same wavelength as quinacrine dihydrochloride 
(Fluorescent Yellow Particle Slide; Spherotec, Inc., Lake Forrest IL). The RBC ghosts were 
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perfused through the parallel plate without quinacrine dihydrochloride - labeled PRPs, so that the 
only fluorescent signal was the beads on the far wall of the chamber. 
5.2.3 Test materials 
Six materials or coatings were analyzed: TiAl6V4 (LaunchPoint Technologies Inc., Goleta, CA, 
USA), methacryloyloxyethyl phosphorylcholine polymer – coated TiAl6V4 (MPC-TiAl6V4), 
silicon carbide (SiC; CoorsTek, Inc., Golden, CO, USA) alumina (Al2O3; LaunchPoint 
Technologies Inc.), yttria partially stabilized zirconia (YZTP; CoorsTek), and Zirconia 
Toughened Alumina (ZTA; CoorsTek). MPC-TiAl6V4 was synthesized using established 
protocols and graciously donated by Dr. Sang-Ho Ye.[88] The materials evaluated were selected 
for their physical characteristics, which were generally compatible with use as blood contacting 
materials in a rotary VAD (see Appendix B).  All samples were cleaned with Simple Green 
(Thermo Fisher Scientific Inc.) and Tergazyme (Alconox, Inc., White Plains, NY, USA) and 
then sonicated three times with distilled water prior to testing to remove the majority of 
contaminates. This protocol was based on the cleaning methods used for rotary VADs 
undergoing preclinical testing.[168] 
5.2.4 Parallel plate flow chamber 
Several flow chamber designs were tested for compatibility with real-time visualization (see 
Appendix A). The final parallel plate flow chamber design was similar to that described by Kent 
et al.[169] The top plate was clear acrylic with angled nylon inflow and outflow luer connectors, 
and the bottom plate was the interchangeable test material. A simple clamping mechanism held 
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the plates together, with a silicone gasket outlining the channel width and length (5 x 8 mm). 
Aluminum shim stock was placed between the plates to provide a precisely defined channel 
height of 0.076 mm (Figure 5.1). The flow within this chamber was assumed to be one-
dimensional laminar parallel plate flow.[83,169] 
 
 
Figure 5.1: Image of the final design of the parallel plate flow chamber. The chamber was clamped between 
the  metal circle and rectangle by screws. Thin aluminum shim stock can be seen along the length of either 
side of the silicone gasket to ensure precise chamber height. 
5.2.5 Blood analog perfusion and image acquisition 
The experimental flow path is presented in Figure 5.2. All non-test surfaces were pacified by 
incubation with 1% bovine serum albumin (BSA, microbiological grade powder; MP 
Biomedicals, LLC, Solon, OH, USA) in PBS for 20 min and rinsed with sterile normal saline 
prior to perfusion. Quinacrine dihydrochloride - labeled PRP was mixed with RBC ghosts for an 
end hematocrit of 25%. This suspension was collected into a 20 mL polystyrene syringe (BD 
Biosciences) and pulled through the parallel plate flow chamber by a syringe pump (Harvard 
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Apparatus, Holliston, Massachusetts, USA) for 5 min at flow rates of 0.118 and 0.295 mL/min 
(wall shear rates of 400 sec-1 and 1000 sec-1 respectively). Platelet adhesion was visualized at 
approximately 4 mm from the inlet leur, in real time, using an inverted epifluorescence 
microscope (Olympus IX FLA, Olympus Corporation, Shinjuku, Tokyo, Japan) with a 40x super 
long working distance objective (PlanFL, phase contrast, working distance 6.5mm - 8.3mm, 
numerical aperture 0.55, and acceptable coverslip thicknesses of 0-2.6mm; Olympus 
Corporation) and a 103W HBO short arc mercury lamb light source (OSRAM GmbH, 
Munich,Germany). Images were acquired every 0.4 sec for 5 min beginning at 1 min after the 
start of perfusion using a CCD camera (PCO-TECH Inc., Romulus, Michigan, USA).  
 
Figure 5.2: Experimental set-up. The virtually transparent blood analog and long working distance objective 
allowed for real time visualization of adherent fluorescent platelets through the flow path onto the opaque 
test surface. The blood suspension was perfused through the chamber across the sample for 5 minutes, and 
real time images were acquired 4mm from the inlet by a CCD camera. 
 
Images were analyzed for the percent of the surface covered by deposited platelets using 
a custom designed MatLab program (MathWorks, Inc., Natick, MA, USA). Briefly, the images 
were converted from grayscale to binary (Figure 5.3 A and B, respectively). All pixels that were 
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brighter than a predetermined threshold were rendered white (platelets) whereas all pixels below 
that threshold were rendered black. The percent area of white pixels was considered to be 
equivalent to the percent area of platelet surface coverage. To visually determine the accuracy of 
the analysis the outline of the original image was overlaid onto the original image (Figure 5.3 
C). 
 
 
Figure 5.3: Pictorial representation of image analysis and platelet surface coverage calculation. Images were 
obtained after 5 minutes of perfusion with SiC. (A) Original fluorescent image. (B) Binary image rendered by 
the MatLab program. (C) Original fluorescent image overlaid with the outline of the binary image. 
5.2.6 Scanning electron microscopy 
Following perfusion, samples were gently rinsed with PBS and incubated with glutaraldehyde 
(2.5% in PBS; Sigma-Aldrich) for 10 min. Next, the materials were washed 3x with PBS and 
dehydrated in consecutive stages of increasing ethanol (Sigma-Aldrich) concentrations. The 
samples were then chemically dried with hexamethyldisilazane (Thermo Fisher). Finally, the 
samples were coated with gold-palladium (Hummer VI Sputtering System, TechnicsWest, Inc., 
San Jose, California, USA) and scanning electron micrographs (SEMs) were obtained (Model 
JSM6330F, JEOL, Tokyo, Japan). 
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5.2.7 Flow cytometry 
Bulk phase activation of the platelets following the addition of RBC ghosts was measured by 
flow cytometry using previously described methods.[148] Briefly, PRP was collected from 
healthy donors using the method described above and separated into two aliquots. RBC ghosts 
were added to one of the aliquots such that the final hematocrit of the solution was 25%, and 
sterile saline was added at the same volume to the other aliquot. Each aliquot was then incubated 
in buffer solution (Tyrode’s solution with 1% BSA, Electron Microscopy Science, Hatfield, PA, 
USA) with fluorescein isothiocyanate – conjugated mouse anti–human CD42b (CD42b, clone 
LG.3A10; AbD Serotec, Raleigh, NC, USA ) and either recombinant phycoerythrin–conjugated 
(RPE) mouse anti-human CD62P or RPE-conjugated isotype- matched control antibody (CD62P 
and Mouse IgG1, clones Psel.KO.2.5 and W3/25, respectively; both from AbD Serotec ) in the 
dark for 20 min. The cells were washed with Tryrode’s solution with 1% BSA and 0.106 M 
sodium citrate dehydrate (Thermo Fisher), centrifuged, and the pellet isolated. The cells were re-
suspended in 1% paraformaldehyde (Sigma-Aldrich) and stored at 4° C (<24 hr) until analyzed. 
CD42b+ events (>5000) were collected on a 3-color FACScan (BD Biosciences) and analyzed 
with WINList software (Verity Software House, Topsham, ME).  
5.2.8 Statistical analyses 
All data are presented as mean ± standard error of the mean. Rheological data were analyzed by 
ANOVA. Flow cytometric data were analyzed by Student’s T test. SPSS v20 (IBM Corp, 
Armonk, NY) was used for all statistical analyses. 
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5.3 RESULTS 
5.3.1 RBC ghost cell rheology 
To verify that RBC ghosts behaved in flow as native RBCs, the rheological properties of RBC 
ghosts were examined by comparing their viscosity as a function of shear rate to that of native 
RBCs. Figure 5.4 A depicts the viscosity response of native and ghost RBCs in plasma under 
shear. No difference between the two curves was found (P=0.61).  Similarly, there was no 
difference in the elongation index of native RBCs when compared to RBC ghosts (Figure 5.4 B; 
P=0.41). This was further confirmed qualitatively (Figure 5.5 A). The translucence of the RBC 
ghosts was also verified qualitatively through the use of immobilized fluorescent yellow beads 
(Figure 5B). Additionally, there was no difference in bulk phase platelet activation between PRP 
and PRP mixed with RBC ghosts (8.7 ± 0.9% and 7.3 ± 0.9%, respectively; P=0.13). 
 
 
Figure 5.4: Rheological comparison of unmodified red blood cells and ghost red blood cells at varying wall 
shear rates. (A) Viscosity. (B) Elongation Index. Data are presented as mean ± standard error of the mean. 
The hematocrit for all samples for both studies was 24%. RBC, red blood cell. 
B A 
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Figure 5.5:Qualitative comparison of unmodified RBCs and RBC ghosts. (A) Unmodified (dark) and ghost 
(light) RBCs during elongation index studies. (B) Parallel plate flow chamber filled with RBC ghosts to test 
translucence. Fluorescent beads immobilized on a glass slide was used as the test material to ensure 
visualization of the far wall of the chamber through the RBC ghosts. RBC, red blood cell. 
5.3.2 Acute platelet adhesion onto test surfaces 
Representative fluorescent images of platelet adhesion to the 6 opaque test surfaces after 5 min 
of perfusion at wall shear rates of 400 sec-1 and 1000 sec-1 are shown in Figure 5.6. These results 
were verified qualitatively through SEM images (Figure 5.7). On the videos acquired during 
these studies, the thrombi grew in elliptical patterns in the direction of flow over time. 
Embolization occurred infrequently, but was present during the experiments. Sequential 
photographs acquired along the flow path following some of the experiments suggested that the 
platelets uniformly reacted with the test materials and were not diffusion-limited from deposited 
platelets at the inlet of the chamber (Figure 5.8). 
25 µm 
B A 
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 Figure 5.6: Representative fluorescent images of platelets adhered to test surfaces after 5 minutes of 
perfusion. (A) TiAl6V4. (B) SiC. (C) Al2O3. (D) YZTP. (E) ZTA. (F) MPC. 
40 µm 
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 Figure 5.7: Representative SEM micrographs of platelets adhered to test surfaces after 5 minutes of 
perfusion. (A) TiAl6V4. (B) SiC. (C) Al2O3. (D) YZTP. (E) ZTA. (F) MPC. 
40 µm 
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 Figure 5.8: Consistent platelet coverage along the length of the parallel plate flow path as determined by 
sequential epifluorescent photographs following a 5 min perfusion with TiAl6V4. 
5.4 DISCUSSION 
Previous methods for examining platelet deposition required that the material be transparent, 
utilized end point analysis, or used PRP instead of blood to perfuse over the surfaces.[170-173] 
Many cardiac devices require structural and mechanical properties that are not able to be met 
with transparent materials. Additionally, the number of materials with known thrombogenicity is 
greatly reduced if opaque materials are not able to be properly evaluated. When end point 
analysis is used to evaluate these opaque surfaces, much of the information between timepoints 
is lost, as real time interactions of platelet deposition and possible embolization are not available 
to the investigator. Observations in these end point systems often involve disruption of the test 
environment, and increasing the number of observations during a single test may introduce 
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errors. PRP may be used to provide a clear testing solution and allow for real time observations 
of platelet-surface interactions, but the test environment may have a reduced relationship to in 
vivo performance, limiting the usefulness of the characterization.  
The use of RBC ghosts mixed with PRP allows for a more physiologically–relevant 
analysis of platelet deposition. Studies utilizing only PRP as the test fluid were not able to mimic 
the near-wall gradient of platelets caused by interactions with native RBCs during blood flow. 
RBCs migrate to the center of the flow path, pushing platelets towards the edges and increasing 
their density near the wall.[165] Models of platelet adhesion suggest that adhesion is dependent 
on near-wall interactions with RBCs.[174] Another model suggests that near-wall platelet-
platelet interactions exhibit longer contact time and total contact area than platelet collisions 
occurring far from the wall.[175,176] This phenomenon has also been reported with in vitro flow 
systems, where the platelet gradient near the test walls enhances the interactions of the platelets 
with the test surface and increases deposition.[177,178] 
The axial migration of RBCs that promotes platelet transportation away from the center 
of vessels is due to unique abilities of RBCs to deform and aggregate, producing a shear-thinning 
effect.[179,180] (Figure 5.4) A similar transport phenomenon was assumed between RBC 
ghosts and platelets due to the similar viscosity and elongation index curves between RBC ghosts 
and native RBCs. The optically clear RBC ghosts were substituted for native RBCs in order to 
maintain this phenomenon of an increased platelet surface gradient near the chamber walls.  
The parallel plate flow chamber design was employed due to its ability to provide well-
developed laminar flow as specified wall shear rates while allowing one side to be 
interchangeable.[83,181] Tubular flow systems have been used successfully in literature for 
platelet studies; however, the capillaries are typically transparent or use end-point 
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analysis.[182,183] Annular flow systems have also been used, with a common variation being 
the cylinder-in-cylinder. However, these also rely on end-point analysis for determination of 
platelet deposition.[184] Milner et al have used a spinning disk in PRP to study platelet 
deposition onto different surfaces.[185,186] The spinning disk technique is attractive as the wall 
shear rate increases along the radius of each interchangeable disk, allowing for a range of wall 
shear rates to be tested on a surface during a single experiment. However, this method relies on 
end-point analysis of the surfaces and the use of PRP as the test fluid. Similarly, cone and plate 
viscometers have been used for platelet testing with opaque surfaces but also rely on end-point 
analysis.[187,188] Additionally, Szarvas et al compared the parallel plate flow chamber to the 
cone-and-plate method and found surface – specific deposition of platelets was best evaluated 
with the parallel plate flow chamber.[189] They also found that bulk phase aggregation of 
platelets occurred more readily in the cone-and-plate method, which may introduce error in 
surface deposition experiments. Zwaginga et al agreed with these observations.[190] 
Schaub et al developed a novel technique using a fiber optic bundle attached to an 
epifluorescent microscope for investigation of the biocompatibility of common mechanical 
circulatory assist surfaces and vascular graft materials in vitro.[83] This bundle could be inserted 
through a diaphragm into the flow path of whole blood, allowing the researcher to observe 
fluorescently labelled platelet deposition temporally on the surface of opaque materials.  The 
investigators looked at several materials such as TiAl6V4, low temperature isotropic carbon, 
diamond – like carbon coating on Ti (DLC), polycrystalline carbon coating (PCD) and 
electrolytically treated titanium alloy (TiO).  The polymeric materials tested were used primarily 
for blood conduits such as expanded polytetraflouroethylene (ePTFE), denucleated ePTFE, 
woven Dacron and collagen impregnated knitted Dacron (HEM).  Using a parallel plate flow 
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chamber, the investigators were able to observe platelet deposition at 60 s intervals for 5 min, 
though with limited resolution and field of view. Additionally, this technique requires the 
observer to disrupt the flow for each observation, which may introduce errors in subsequent 
timepoints.  
5.5 LIMITATIONS 
One limitation to this study is that it was an acute in vitro analysis. The test materials were 
subjected to blood analog perfusion for five min, whereas the tested materials would be 
implanted for much longer periods of time (months to years). However, when determining an 
alternative material for in vivo testing it would be more ideal to select a surface that has very 
little platelet surface coverage after 5 min compared to surfaces that promote the formation of 
large thrombi within the same period of time. Another limitation to this study is that we used a 
hematocrit of only 25%. Although this is lower than the average hematocrit of healthy 
individuals, this blood composition is typical for patients implanted with VADs.[191] Another 
limitation is that this was a 2-dimensional analysis. We were not able to effectively measure 
thrombus formation in the Z direction, which reduced the information we were able to obtain on 
each experiment. However, we assumed that any thrombus growth in the Z direction would be 
the result of platelet-platelet interactions and would be minimally affected by the properties of 
the test material.  
 103 
5.6 CONCLUSIONS 
Determining the in vitro thrombogenicity of surfaces is an important step in developing and 
selecting new materials for use in blood-wetted devices. A method was developed for the 
analysis of time- and flow- dependent platelet adhesion on opaque surfaces in real time. This 
method allows for an increased number of biomaterials to be examined in vitro under 
physiologically–relevant conditions. An improved understanding and characterization of acute 
thrombogenicity of opaque materials may encourage innovation in the utilization of alternative 
materials in cardiac device design. 
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6.0  CONTINUED RESEARCH AND FUTURE DIRECTIONS 
The studies presented in the previous sections add to the scientific knowledge of the body’s 
immunological and hemostatic response to VAD implantation. This information also lays the 
groundwork for additional research that will continue to advance the field. The following are 
research opportunities outside of the objectives of this dissertation that have become available as 
a result of the work contained herein.  
6.1 IMMUNOLOGICAL RESPONSES TO VAD IMPLANTATION 
6.1.1 Impact of VAD support on granulocyte activation, dysfunction and apoptosis 
As stated previously, inspiration for this research came, in part, from a series of in vitro studies 
from Shive et al. revealing an increase in apoptosis and dysfunction among granulocytes and 
monocytes exposed to high fluid shear stresses.[106,107,192] The first paper in the series 
revealed that bacteria has a stronger ability to adhere to artificial surfaces (specifically 
segmented polyurethane (PEUU)) under high fluid shear stresses than polymorphonucleocytes 
(PMNs).[192] The study went on to show a decrease in the ability of PMNs pre-exposed to high 
fluid shear stresses to produce reactive oxygen species (ROS) when stimulated. (Table 6.A) 
Though the PMNs pre-exposed to high shear stresses exhibited a diminished ability to produce 
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ROS upon stimulation. Interestingly, the shear stresses investigated were designed to be 
physiologically relevant and possibly far below the super-physiologic shear forces exhibited by 
VADs. The authors suggest that an inverse relationship may exist between PMN stimulation 
dysfunction and shear stress exposure. 
 
Table 6.A: ROS released from PMNs before and after exposure to shear flow. From Shive et al. [192] 
 
 
The inability of neutrophils to remain adherent to PEUU under shear forces prompted 
further investigation from this same research group. As a result, Shive et al found that 
neutrophils adhered to PEUU underwent shear-dependent apoptosis. (Figure 6.1) In an elegant 
study, the authors report nearly total apoptosis of adherent neutrophils at relatively low shear 
stresses, with the neutrophils exhibiting a more pronounced apoptotic response to shear than to 
standard chemical induction. The authors hypothesized that the artificial surfaces found in 
cardiac devices may induce apoptosis among neutrophils, decreasing the population of innate 
immune cells available to defend against invasion from microbes. Since neutrophils make up the 
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vast majority of the immune system’s initial response to microbe infiltration, apoptosis of these 
cells may leave the host at a much higher risk of infection. 
 
 
Figure 6.1: Shear-dependent apoptosis of neutrophils adhered to PEUU. From Shive et al. [107] 
 
Similarly, a third report by Shive et al investigated the effect of fluid shear stress on 
monocyte adhesion and apoptosis.[106] The authors reported a shear-dependent apoptotic 
response among adherent monocytes comparable to but weaker than the response displayed by 
neutrophils. Again the authors hypothesized that apoptotic reduction of the number of available 
monocytes may expose the host to an increased risk of infection. 
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 Figure 6.2: Shear-dependent apoptosis of monocytes adhered to PEUU. From Shive et al. [106] 
 
As state previously, expression of MAC-1 has been reported to be a modulator of 
granulocyte apoptosis. MAC-1 expression on granulocytes was not reported by Shive et al, nor 
was it investigated in rotary VAD patients prior to the studies described in Section 3.0. The 
elevated levels of MAC-1 expression found in HeartMate II patients (and to a lesser extent, 
HeartWare and Thoratec pneumatic) suggest that these patients will likely also have an 
elevated percentage of apoptotic granulocytes. Interestingly, among the leukocyte-derived 
microparticles described by Diehl et al, many expressed MAC-1.[136] Although the specific 
leukocyte origins of the microparticles were not reported, these may be the apoptotic 
remnants of activated circulating granulocytes.  
 The first report by Shive et al suggests that granulocyte dysfunction may also be 
increased following VAD implantation.[192] The elevated levels of MAC-1 expression found on 
HeartMate II patients were not associated with infection, and were therefore assumed to be 
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expressed in error by cell to other stimuli. Similarly, circulating granulocytes may also be 
induced to release their ROS contents through interactions with the VAD surface or shear 
stresses in the pump. Studies involving cardiopulmonary bypass have reported a decreased ROS 
response by granulocytes to stimuli.[193] Further studies into granulocyte dysfunction could 
include an investigation of granulocyte ROS response before and after VAD implantation. 
In addition to the granulocyte data presented in Section 3.0, monocyte expression of 
MAC-1 in VAD patients following implantation was also measured, though with limited success. 
Figure 6.3 shows the long- and short-term expression of MAC-1 in VAD patients. Though the 
overall trend appears to be reduction in monocyte activation following VAD support, no 
differences could be found either with respect to time or by device implanted. One possible 
reason for this was that the available monocyte population for each patient slowly disappeared 
following implantation. It was common for implanted patients to have less than 300 monocytes 
per 100 µL of blood as determined by FSC, SSC and expression of CD14 by flow cytometry 
(suggested analysis is at least 2000 cells). There are two probable explanations for the 
disappearing monocytes. The first cause could be that monocytes were lost during the 
processing of the flow cytometry samples. Monocytes are notoriously difficult to handle as they 
are known to adhere to most surfaces, and would be even stickier if they were activated from 
the presence of the VAD. Many of the monocytes may have simply stuck to the sides of the 
blood collection tubes and the polystyrene tubes used for flow cytometry analysis. Another 
possibility is that the monocyte population decreased over time due to shear-induced 
apoptosis, similar to that described by the in vitro studies by Shive et al.[106] Other studies 
have shown monocyte activation following VAD implantation, though these were conducted 
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with patients implanted with previous-generation devices.[57] This possibility may also help to 
explain the trend towards a reduction in monocyte expression of MAC-1, as the activated 
monocytes may have been quickly removed from circulation and were slow to return to a 
normal population. Unfortunately, in the hands of this author, the number of events available 
for analysis was too small and the data was had too high of a variance to make an definitive 
statements, but this topic may be of interest to in future studies. 
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Figure 6.3: Macrophage antigen-1 (MAC-1) expression on circulating monocytes in a subset of ventricular 
assist device patients following implantation. (A) MAC-1 expression in all three devices evaluated to 1 month 
post-implant. (B) MAC-1 expression in HMII and HW patients to postoperative day 120, and PVAD to day 
60. Data presented as mean plus standard error of the mean. The “0” on the abscissa indicates preoperative 
values. HMII, HeartMate II; HW, HeartWare; PVAD, Thoratec pneumatic VAD. 
6.2 THROMBOSIS AND HEMOSTASIS FOLLOWING VAD IMPLANTATION 
A striking result among the data presented in Section 4.0 was the overwhelming influence of pre-
operative hepatic health on post-operative blood product consumption and bleeding 
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complications. This author had hypothesized that the type of device would be the determining 
factor for bleeding and thrombosis experienced by patients following implantation. The different 
flow fields, blood-contacting materials and shear rates between pulsatile and continuous flow 
VADs were expected to produce different adverse event rates as well as different concentrations 
of plasma indicators of thrombosis. Moreover, these differences between VAD types had already 
been found to have contributed to the immunological differences presented in Section 3.0. 
Instead, patient-related factors proved to have a great influence on the immediate post-operative 
clinical course of the patient. Utilization of the health assessment scores for patients as a 
predictor of bleeding may be an important tool for proper post-operative treatment of VAD 
patients. 
Future studies building off of the data presented here could measure the circulating levels 
of various liver-dependent coagulation factors temporally in VAD patients following 
implantation. The main aim of the study would be to correlate pre-operative measures of liver 
health (e.g. MELD score) with post-operative coagulation factor levels and bleed product 
consumption. Coagulation proteins synthesized in the liver and therefore candidates for 
measurement would be factors I (fibrinogen), II, V, VII, IX, X and XI, as well as proteins C and 
S, and antithrombin. One variation of this study would be to measure the coagulation factors a 
frequent timepoints throughout the peri-operative period to determine the average time required 
to for each factor to reach hemostasis. While the administration of factor-rich products may 
artificially inflate some of the values, these products appear to be only minimally effective at 
correcting hemostatic imbalance in the face of hepatic dysfunction.  
Another variation on this study would be to measure these same factors at much later 
timepoints such as at 1, 3 and 6 months of support. The rationale for this approach builds upon a 
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study by Yang et al that investigated changes to measures of hepatic health (including MELD 
score) after VAD implantation.[146] The authors found some signs of worsening liver function 
(such as hyperbilirubinemia) at 30 days post-implantation, and these values did not improve until 
3 to 6 months after implant. (Table 6.B) A similar trend may exist among clotting factors. 
 
Table 6.B: Dynamics of patient variables before and after VAD implantation. From Yang et al. [146] 
 
 
Despite the relative homogeneity of bleeding and thrombosis responses between VADs 
found in Section 4.0, device design may still be a significant contributing factor to a VADs 
overall thrombogenicity. Determination of this thrombogenicity in patients may only be possible 
at much further timepoints than those presented in recent literature. If liver dysfunction remains 
persistent in VAD patients at 2 to 3 months post-implantation as suggested by Yang et al, then 
 112 
any attempt at measuring indices of thrombosis between implanted devices before this time may 
be masked by patient-related effects.[146] Interestingly, differences in D-dimer levels among the 
patients presented in Section 4.0 did not become significant until 25 and 55 days post-implant, 
with trends suggesting that the HeartMate II would continue to have elevated values over the 
other pumps. (Figure 4.4) Studies with longer periods between implantation and assessment 
timepoints may help to reveal thrombotic differences between pump designs by allowing the 
patient-related effects enough time to subside. A combination of long-term measurements of 
coagulation factors combined with longitudinal assessment of VAD thrombogenicity may 
eventually allow clinicians to understand the transition from patient-dominant effects to pump-
dominant effects. This information may then allow clinicians to alter anticoagulation and anti-
platelet regimens to match the source of hemostatic imbalance. 
6.3 REAL-TIME VISUALIZATION OF PLATELET DEPOSITION ONTO OPAQUE 
SURFACES UNDER FLOW 
The suspension composed of red blood cell ghosts and platelet rich plasma described in Section 
5.0 proved to be an acceptable blood analog for use in platelet deposition studies.  Section 5.3.1 
described the similarity in rheological properties between the unmodified and ghost red blood 
cells. Several studies have found an increase in the amount of circulating leukocyte- and platelet-
derived microparticles in patients implanted with continuous-flow VADs.[136,194] (Figure 6.4) 
Other investigators have suggested that microparticles encourage a pro-thrombotic state in the 
cardiac patients through exposure of phosphatidylserine surfaces and tissue factor 
expression.[195,196] In order to further improve on the blood analog solution as a model of a 
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VAD patient’s native blood composition, the addition of leukocyte- and platelet-derived 
microparticles could be added to enhance the reactivity of the platelets with the artificial 
surfaces. Creation of the microparticles and determination of microparticle concentration could 
be performed using established protocols. The microparticles could be added to the suspension 
immediately prior to the perfusion, or it could be joined to the perfusion solution through a Y 
connection proximal to the flow chamber. The influence of microparticles on platelet deposition 
could be studied by keeping the test material constant and varying the microparticle 
concentration in the blood analog (between no microparticles (control) and low, medium and 
high concentrations derived from literature). 
 
    
Figure 6.4: (Left) Increase in platelet-derived microparticles between VAD patients and heart failure 
controls. From Deihl et al.[136] (Right) Example of leukocyte-derived microparticles following 6 hours of in 
vitro human blood circulation with  the VentrAssist LVAD. From Chan et al.[194] PMP, platelet-derived 
microparticles; LMP, leukocyte-derived microparticles. 
 
Many cardiac devices are composed of assembled or mated components which inevitably 
creates crevices along the flow path. These crevices may become a nidus for thrombus formation 
through flow disruption or stagnation. Application of the method described in Section 5.0 to a 
step or crevice could help to better understand thrombus dynamics around this common 
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geometry in cardiac devices. To help visualize the development of the thrombus over time, the 
red blood cell ghost and platelet rich plasmas suspension could be divided into three aliquots, 
with each aliquot labeled with a dye with different spectral characteristics. Each aliquot could 
then be successively perfused over the crevice or step. Rotation of the microscope filter set could 
allow tracking of platelet deposition from the current dye as well as tracking of differently 
labeled dyes from earlier in the experiment. This experiment may be able to help provide 
information on the progression of thrombus formation. Periodic collection of the effluent and 
subsequent analysis with flow cytometry may allow for mapping of the composition of the 
emboli and provide information on the dynamics of platelet embolization. 
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7.0  FINAL CONCLUSIONS 
Ventricular Assist Devices (VADs) have become an established treatment for advanced heart 
failure, prolonging the life of patients when used as a bridge to transplantation or as destination 
therapy. VAD support is challenging due to the amount of surface area exposed to blood and the 
intended length of time for support, representing one of the most difficult environments in which 
to place a medical device. Even though device enhancements and increased experience among 
implanting institutions has improved the overall quality of life for patients support by VADs, 
these patients remain vulnerable to biological complications present during the infancy of this 
technology.  
Infection remains an ongoing risk during VAD support, regardless of the length of 
support. While there are many factors that influence a patient’s risk for infection, few studies 
have reported on the impact of VAD implantation on leukocyte function and number, and many 
of these studies involved previous generation devices. 
A series of studies with HeartMate XVE patients focused on selective reductions in 
adaptive immune cell populations following implantation. Ankersmit et al found a significant 
and specific decrease in CD4+ T cells.[101] Subsequent reports revealed that the CD4+ T cell 
depletion may have caused non-specific B cell hyperactivity in these patients. The effects of this 
immune state were found to be longer transplant wait times and hospital stays, both of which 
increase health risks and costs to the patient.  
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The Ankersmit et al study was used as template to study the effect of implantation of the 
currently-utilized HeartMate II rotary LVAD on circulating T cells.[101] HeartMate II patients 
exhibited similar pre-operative levels of circulating adaptive immune cells as well as CD4/CD8 
T cell ratio. However, HeartMate II patients did not exhibit the same selective reduction in CD4 
T cells as was found in HeartMate XVE patients. When extended to 4 months after implantation, 
no differences were found in CD4 or CD8 T cell levels. Even though there appeared to be a 
different response in adaptive immune cells between implantation of the HeartMate XVE and the 
HeartMate II, the HeartMate II patients in this study still experienced a substantial risk to 
infection. Sensitization following HeartMate II implantation also remained a problem.  
Given the vastly different flow patterns, shear stresses and blood contacting surfaces of 
the two VADs, it was not surprising that the two sets of patients responded differently following 
implantation. The unregulated pseudo-endothelialization of the surfaces of the pulsatile 
HeartMate XVE combined with longer contact time between this bioactive surface and 
circulating blood components may have contributed to a reduction in circulating CD4 T cell 
numbers by selective apoptosis. In contrast, the polished titanium of the rotary HeartMate II 
resists cellular adhesion and prolonged leukocyte interactions. Despite these differences, the 
HeartMate II patients continued to be plagued by similar infection and sensitization outcomes 
found in earlier generation devices such as the HeartMate XVE. This research suggests that there 
may still be immunological compromise among current-generation VAD patients, but these 
alterations may be influenced more by the response of innate immune cells following 
implantation rather than the adaptive immune system. 
There is a paucity of research presented on the response of circulating leukocytes 
following VAD implantation. Many studies understandably focus on the occurrence of infections 
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in VAD patients, with information like location, severity, frequency and outcomes; however, 
these studies largely ignore investigating the underlying cellular impact of VAD support. The 
cause for infection was often assumed to be the existence of a percutaneous driveline providing a 
pathway for infectious agent migration. Few studies presented temporal immune cell data in 
VAD patients, and even fewer investigated the response of the innate immune system following 
VAD support.  
This research found that the systemic immunological response to VAD placement, either 
through surgical insult or the presence of the device, to be substantial and more pronounced than 
other cardiac surgeries. The sharp rise in circulating leukocytes presented in this research has 
been presented in other reports of valve replacement surgeries or cardiopulmonary bypass 
support, but the average time for resolution of this spike was much shorter than was found in 
VAD patients.  
Additionally, the type of device implanted may influence post-operative immune 
response experienced by the patient. Granulocyte activation, as measured by expression of 
macrophage antigen-1, was significantly higher in HeartMate II patients than those supported 
with either a HeartWare or Thoratec pneumatic LVAD, and lasted for a longer period of time 
than levels reported for cardiopulmonary bypass circuits. Expression of macrophage antigen-1 
mediates extravasation of the circulating granulocytes into surrounding tissue beds, reducing the 
number available for immune defense and promoting edema. Expression of macrophage antigen-
1 can also be a precursor to apoptosis, further reducing infection resistance. This may help to 
explain the similar occurrence of infection events between the HeartMate II and Thoratec 
pneumatic LVAD patients even though the HeartMate II has a substantially smaller driveline exit 
site. In contrast, HeartWare patients exhibited little granulocyte activation and significantly less 
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infection events than either the HeartMate II or the Thoratec pneumatic LVAD. This research 
suggests that circulating immune cell activation and infection risk may be influenced by VAD 
design, though the principle variables and factors involved have not yet been determined. 
VAD patients also remain at considerable risk for bleeding and thromboembolic 
complications. VAD support is typically reserved for some of the very sickest patients, often 
with pre-operative conditions predisposing to coagulopathies. Investigation into pre-operative 
indices that could predict post-operative bleeding and thromboembolic complications could be of 
benefit to clinicians to improve patient selection and post-implant patient hemostasis and 
anticoagulation management. Recent studies have demonstrated a correlation between the Model 
for End-Stage Liver Disease (MELD) score with peri-operative bleeding and post-operative 
morbidity and mortality. High MELD scores may indicate multi-organ failure and hepatic 
congestion. Liver impairment may in turn lead to hemostatic imbalance and disregulation.  
This research found that pre-operative hepatic and renal dysfunction appears to have 
immediate and long lasting hemostatic effects on patients implanted with the HeartMate II, 
HeartWare or Thoratec pneumatic LVADs. MELD score was a positive predictor of post-
operative blood product administration, chest tube drainage and bleeding adverse events 
regardless of the VAD implanted. When multivariate linear regression analysis was performed 
on total blood product administration, MELD score was a significant pre-operative predictor 
along with age and mean pulmonary artery pressure. VAD patients with high pre-operative 
MELD scores exhibited significantly different temporal trends of thrombin generation and 
platelet counts, as well as protracted fibrinolysis. Though the rate of adverse events decreased 
markedly after the first 2 days of implantation, the sub-clinical effects of a high pre-operative 
MELD score on the hemostatic system appeared to be persistent, though the manifestation of this 
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influence is still to be determined. Surprisingly, the type of VAD implanted during this study 
was not a significant factor in any of the peri-operative bleeding measurements despite very 
different surgical implantation techniques and VAD hemodynamic profiles. Similarly, no 
difference was found between devices among the hemostatic markers followed except for higher 
D-dimer concentrations in HeartMate II patients at further timepoints, which may reflect ongoing 
fibrinolysis at the unique textured inflow cannula. 
Heavy reliance on anticoagulation medications to balance hemostasis in VAD patients is 
a common and imperfect solution to prevention of thromboembolic complications. Prolonged 
therapeutic anticoagulation is often difficult, and patients that fall outside of the therapeutic 
range are often at great risk for hemorrhagic or thromboembolic stroke. The utilization of 
surfaces other than titanium as the blood contacting surfaces of circulatory support devices may 
improve the hemocompatibility performance of these devices, possibly decreasing the necessity 
of anticoagulation and anti-platelet agents and improving outcomes. Since many potential device 
materials are opaque, development of an in vitro method for assessing these materials could be of 
considerable value to VAD designers. 
Prior methods for examining platelet deposition required that the material be transparent, 
utilized end point analysis, or used platelet rich plasma instead of blood to perfuse over the 
surfaces. End point analysis may produce misleading results due to the limited information 
provided, and platelet rich plasma had a reduced near-wall platelet gradient compared to whole 
blood. This research produced a method for the analysis of time- and flow- dependent platelet 
adhesion on opaque surfaces in real time using a physiologically-relevant blood analog solution. 
The blood analog solution was composed of optically transparent red blood cell ghosts and 
fluorescently dyed platelet rich plasma. The red blood cell ghosts exhibited rheological 
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properties similar to unmodified red blood cells. A parallel plate flow chamber was developed 
that allowed for visualization of the surface of the opaque test materials through the flow path 
using an inverted microscope with a long working distance objective. This method produced 
videos of platelet deposition onto a variety of opaque test materials such as TiAl6V4, zirconia-
toughened alumina, yttria partially stabilized zirconia, alumina, silicon carbide and 
methacryloyloxyethyl phosphorylcholine polymer – coated TiAl6V4 at wall shear rates of 400 
and 1000 s-1. The final images of these videos were confirmed through scanning electron 
micrographs. This novel method for observing platelet deposition allows for an increased 
number of biomaterials to be examined in vitro under physiologically–relevant conditions. 
Assessment and utilization of less-thrombogenic materials as the blood contacting surfaces of 
cardiac devices (such as VADs) could greatly improve the performance of these devices in the 
patient. Since many cardiac devices are metallic, this newly developed method for assessment of 
platelet deposition could encourage innovation in material selection. 
This body of research presented above may impact the VAD community through a 
variety of pathways. Hopefully these chapters will spark further investigations on immunological 
changes in VAD patients. Future research on immune cell responses to VAD implantation may 
focus on the innate immune cells and shift away from the adaptive system. The author does not 
suggest that VADs do not impact the adaptive system; rather, by underlining the uniqueness of 
the HeartMate XVE LVAD, this research should encourage the formation of new theories and 
paradigms to investigate in currently-utilized devices. These new paradigms may feature a 
renewed appreciation for alterations in innate immune cells exposed to artificial surfaces and 
super-physiological shear rates. Further research into these alterations may influence future VAD 
design to prevent infection as leukocyte responses appear to be device-specific.  
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This research may impact future clinical research and practice by highlighting the 
importance of pre-operative hepatic health of the VAD patient on post-implant hemostasis. 
While the association of hepatic dysfunction with morbidity and mortality among VAD patients 
has been presented previously, this research investigated the influence of hepatic dysfunction on 
blood product consumption and circulating biomarkers of hemostasis in current generation 
VADs. This research may help to encourage referring physicians to consider VAD support in 
advanced heart failure patients prior to the onset of hepatic congestion. Clinicians may be able to 
better predict the blood product requirements and anticipated coagulopathies for VAD patients 
and develop therapies to reduce these requirements prior to surgery. Also of note for clinicians is 
that the pre-operative hepatic health of the patient was a much stronger predictor of blood 
product consumption than the type of device implanted. This suggests that any perceived 
hemocompatibility advantages between VAD designs may not be realized until later in the 
support period. 
The ability to assess platelet deposition onto opaque materials in real time under varying 
shear conditions may impact future material design and selection for cardiac devices as well as 
encourage further research of platelet interactions with artificial surfaces. This novel method 
may help to promote innovation among cardiac device developers as new materials may be 
assessed in vitro for thrombogenicity. The in vitro assessments may also help to improve 
resource efficiency during device development as many previous device designers had to rely on 
unreliable end-point analysis experiments or risk catastrophe in expensive pre-clinical animal 
studies. This novel method has been successfully used to identify four materials with better 
biocompatibility performance than the oft-used TiAl6V4 as a blood contacting surface, while 
another surface that was superior to TiAl6V4 by end-point analysis may actually be much worse 
 122 
as it encourages platelet build-up and embolization. Further application of this assessment 
method may be to investigate the influence of steps and crevices on thrombus formation on 
opaque surfaces, such as those found along the seams of joining components of VADs. 
 
 
 
 123 
APPENDIX A 
PARALLEL PLATE CHAMBER DESIGN RATIONALE AND HISTORY 
A.1 INTRODUCTION 
As discussed in Chapter 5, the parallel plate flow chamber design was employed due to its ability 
to provide accurate control of instantaneous flow conditions while allowing one side of the 
chamber to be interchangeable (as opposed to tubular and annular flow chambers).  Several 
chamber designs in the literature were attractive, most notably the Poiseuille flow from the 
design by Chung et al that allowed for a wide, uniform distribution of wall shear forces (Figure 
1, left); however problems with this design were the crevices present from the way samples were 
held in the flow field and possible recirculation in the temporary reservoir above the inlet 
opening.[181]  Both of these problems would possibly introduce increased activation of the 
platelets through stagnation or recirculation zones. These recirculation zones could increase the 
local concentration of platelet activating agents released from alpha and dense granules from 
deposited platelets.  Instead, the design of the parallel plate chamber was similar to that used by 
Schaub et al (Figure 1, right), except without the ports for introducing the fiber optic bundle 
(Schaub et al).[83] However, this chamber design contained a small step where a gasket was 
necessary to seal the chamber where the material and the chamber meet, both at the inlet and 
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outlet.  The effects of this step on the assessment of the materials may be limited by decreasing 
the size of the step as much as possible and by examining the surface of the test materials far 
enough away from the entrance that any flow disruption has diminished and laminar flow may be 
assumed.   
 
      
Figure 7.1: The flow chambers used by Chung et al (left) and Schaub et al (right) [83,181] 
 
Numerically, the design of the flow chamber can be reduced to the three parameters of 
plate shear stress, Reynolds number and entrance length [197], which are defined as: 
 
Equation 1: Wall Shear Stress 
 
Equation 2: Reynolds Number 
 
Equation 3: Entrance Length 
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Limiting the height of the flow chamber will decrease the Re and the entrance length 
effects while making the height too small may cause excessive shear stress and shear rates. The 
wall shear rates selected for testing were 400 and 1000 s-1 based on approximations for the range 
of shear rates platelets may be expected to experience in blood-wetted medical devices. These 
formulas were used to set the flow rate on the syringe pump used in the studies and to calculate 
the amount of blood needed for a 5 min perfusion.  
A.2 FLOW CHAMBER DESIGNS 
A.2.1 Polycarbonate 
The first generation flow chamber was designed by Dr. Trevor Snyder at the University of 
Pittsburgh and was tested by the author (Figure 2). The flow chambers were three separate 
polycarbonate pieces glued together to form the inflow track for the fluid, one side of the parallel 
plate, and the outflow track for the fluid. The other side of the parallel plate consisted of the 
interchangeable test materials. The three glued pieces formed a gradual widening flow path 
towards inlet and outlet openings at the test surface, while a silicon gasket was used to define the 
height and width of the flow path over the test material. Polycarbonate was chosen as the plate 
material due to its transparency and observations of its resistance to platelet deposition during 
other biocompatibility assessments within the laboratory. 
Several problems became apparent with this design during initial testing. All of the flow 
chambers failed at the glued interlocking edges before significant data was collected, resulting in 
leaking and breaking apart (Figure 3).  The machining costs for repairing or replacing the 
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chambers were high and the lead time was several weeks for any repairs, so any problems with 
the chambers caused substantial delays with testing.  The flow path of each chamber had many 
seams and cracks due to unavoidable imperfections in machining and difficulties with assembly. 
The silicon gasket was able to define the width and length of the blood flow path as designed, 
but the height of the flow path was not well controlled. Further modifications were necessary to 
control the flow path height as this was a critical variable for determining wall shear rate. The 
polycarbonate was also found to be highly autofluorescent, especially in the wavelengths most 
commonly used in yellow-fluorescent platelet dyes (such as quinacrine dihydrochloride).This 
autofluorescence made real-time visualization of thrombus growth impossible. The first efforts in 
the biocompatibility characterization of opaque blood-contacting materials (such as titanium) 
consisted of measuring platelet activation after contact with the material by collecting the 
effluent and observing platelet adhesion at the end of each test through microscopy (end-point 
analysis). No useful data was obtained through these experiments.   
 
 
Figure 7.2: The first generation polycarbonate parallel plate flow chamber clamped onto TiAl6V4 
(bottom). A simple C-clamp provided the clamping pressure, and a silicon gasket was used to define the flow 
path width. Flow path height was not well controlled. 
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 Figure 7.3: The first generation polycarbonate parallel plate flow chamber following repair after 
breaking.  Notice the rough edges of the flow path as well as the apparent leaks at the chamber junctions. 
A.2.2 Polydimethylsiloxane 
The failure of the polycarbonate chambers prompted the investigation of simpler and more 
efficient designs.  The second generation of flow chambers utilized polydimethylsiloxane 
(PDMS) as the chamber material due to the reduced cost and effort of fabrication (using a mold 
instead of machining) and the material properties of the PDMS (allowing for self-sealing of the 
chamber instead of using a gasket) (Figure 4).  Similar to the polycarbonate design, these 
chambers also focused on effluent collection and end-of-study microscopy to measure platelet 
activation and deposition as the thickness of the PDMS did not allow for visualization of the 
sample surface while in the flow chamber during testing.  However, the PDMS was much easier 
to manipulate, eliminating the rough edges found in the polycarbonate chamber and removing 
the gasket which caused a “step” at the inlet and outlet of the flow path. 
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Figure 7.4: Second generation parallel plate flow chambers made of PDMS. The inlet and outlet was 
constructed of silicon i.v. tubing and the rest of the surfaces were PDMS. In these pictures, glass was used as 
the test material and water with green dye was used to illustrate the flow path. 
 
Blood-perfusion studies performed with these prototypes suggested that real-time or 
periodic visualization of platelet deposition on the test surface during perfusion could be 
possible. Unsuccessful attempts were made to visualize the surface of the test materials through 
the PDMS due to the thickness of the chambers. To accommodate visualization, a third 
generation flow chamber was made with less PDMS (to make it thinner) and the inlet and outlet 
angles were made more horizontal with regards to the flow path so as to provide a viewing 
window for the microscope objective.  These improvements, combined with modifications to the 
perfusion protocol and blood (quinacrine dihydrochloride – dyed PRP combined with RBC ghost 
cells, discussed in Chapter 5) allowed for visualization of platelet deposition during testing. 
The second and third generation flow chambers were fabricated by curing PDMS around 
a mold of the flow path.  To precisely control the height and width of the flow channel 0.2” strips 
of very flat brass or aluminum alloy shim stock were bent at two places, 0.7” apart, with 3/32” 
ID Tygon tubing shoved over each end of the strip.  The height of the flow channel was 
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determined by the thickness of the shim stock used in the mold. In order to reduce the blood 
volume necessary for these studies , 0.015”, 0.010” and 0.005” –thick shim stock was used. The 
shim and tubing apparatus was attached to a flat metal disc with a very thin layer of weak glue 
and compressed using a rare-earth magnet and metal rods (Figure 5). After drying, excess glue 
was removed from the edges of the shim and the mold was placed in a polystyrene dish. Silgard 
184 PDMS (Corning) was poured into the dish, degassed and cured using a vacuum oven 
(Figure 6). After curing, the chamber was removed from the dish and the round metal disc was 
carefully removed to reveal the shim strip in the PDMS. The shim strip was cut and each half 
was pulled out of the PDMS, leaving the tubing partially embedded as the inlet and outlet ports 
for the chamber. The tubing was further secured to the PDMS by application of silicone glue at 
the intersections of the tubing PDMS. The resultant flow chambers had a smooth, continuous 
flow path that gradually transitioned the flow path from circular tubing to rectangular parallel 
plate and then back to circular tubing without apparent steps or crevices and with precise channel 
dimensions (Figure 7).  
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Figure 7.5: Flow chamber mold prior to encapsulation in PDMS.  The brass shim strip will produce the blood 
flow path and is glued to the stainless steel round shim disc on the bottom. The mold is pictured on top of the 
rare-earth magnet, used to stabilize the mold in the polystyrene dish as the PDMS is poured. 
 
 
 
Figure 7.6: PDMS chamber in the polystyrene dish after curing in a vacuum oven. When removed from the 
dish, the round steel shim on the bottom easily breaks from the brass shim strip and is removed from the 
chamber.  The brass is then cut and pulled from each end, leaving the tubing and flow path behind. 
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 Figure 7.7: A finished PDMS parallel plate flow chamber. The chamber is viewed from the top with a glass 
microscope slide used as the material sample on the bottom.  Excess PDMS around the edges of the chamber 
has been trimmed to fit the microscope stage insert described below.  The large mounds of clear polymer 
where the tubing intersects the PDMS is silicon glue applied to provide additional mechanical support to the 
tubing.  The flow path for this picture is visible through the use of a green dye. 
 
An inverted epifluorescent microscope was used for the real time visualization of 
platelets through the PDMS chambers. Since the chambers would have to be in an inverted 
position on the microscope, a robust clamping mechanism was necessary. Two different 
clamping mechanisms were tested for sealing the PDMS chambers to the test materials. The first 
mechanism consisted of a grooved acrylic plate (which fit as an insert in the stage of the inverted 
microscope) with two side clamps along the edge of the fluid flow path of the chamber. (Figure 
8) The side clamps allowed for a viewing window for the microscope. This clamping mechanism 
was not successful in maintaining a seal during the flow experiments due to the flexibility of the 
PDMS chambers; once the apparatus was inverted on the microscope, both the inlet and outlet 
portions of the flow chamber would bend slightly downwards and break the seals along the inlet 
and outlet of the fluid path. It was also difficult to attain equal distribution of force on the 
flexible chambers, and bulging could be seen between the two clamps. These problems were 
corrected with the second clamping mechanism, which consisted of the same acrylic plate but 
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used a solid bar with a window cut out as the clamp. (Figure 9) The bar distributed the clamping 
force more evenly on the chamber, and was able to provide a more reliable seal than the side 
clamps. 
 
     
Figure 7.8: Side clamps for the PDMS flow chambers to help maintain a seal with the sample material when 
overturned on the inverted epifluorescent microscope. The clear base holding the clamps is the microscope 
state insert.  The semi-circle on each clamp allows the microscope objective closer access to the PDMS 
chamber and a shorter working distance to the material sample surface (titanium is the material sample in 
these pictures). 
 
 133 
     
Figure 7.9: A plate clamping mechanism for sealing the PDMS chambers. The plate provided a larger area of 
force and possibly provided a more uniform pressure distribution and robust seal.  The plate was made of 
stainless steel and the clear base was a microscope stage insert. The test material in the picture was titanium. 
 
Visualization of platelet deposition on the near wall of the chamber revealed that 
unmodified PDMS was moderately thrombogenic (Figure 10).  Platelet activation caused by the 
PDMS could introduce significant error into the system through the release of agonists from 
activated platelets (such as adenosine diphosphate). In order to mask the surface and make it less 
thrombogenic, the chamber (without the sample material) was incubated in 4% bovine serum 
albumin dissolved in PBS for 15 min and then washed with PBS to remove excess protein.  
When platelet perfusion studies were repeated, there was a marked decrease in the amount of 
platelets deposited on the surface of the PDMS (Figure 10). The albumin coating appeared to 
reduce the platelet deposition on the non-test surfaces such that any potential error from the non-
test surfaces was effectively pacified. This albumin incubation step was then used in all further 
flow chamber experiments and is briefly described in Section 5.2.5. 
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Figure 7.10: The near wall surface of the PDMS parallel plate flow chamber after 5 min of perfusion with 
quinacrine dihydrochloride labeled whole blood at 1000 s-1. The near wall surface consisted of the unmodified 
PDMS chamber (left) or the PDMS chamber incubated with 4% BSA for 15 min and rinsed with PBS prior 
to blood contact.  Microscope magnification was 600X for both images. 
 
Using the bar clamp apparatus, real-time visualization of platelets onto opaque surfaces 
with the incorporation of ghost red blood cells was first performed with this third generation 
PDMS flow chamber design. However, there were several problems that became apparent during 
experiments. Although the bar clamp provided a more reliable seal between the PDMS chamber 
and the test material, the seal would still fail during some experiments and introduce air bubbles 
into the flow path. The air bubbles would either stop the fluid flow (if the seal was broken at the 
outlet port) or would wipe away all platelets on the surface of the material (if the seal was broken 
at the inlet port). Similar to the polycarbonate chambers, the length and width of the fluid path 
was well defined but the height of the path could not be determined. The clamping pressures 
needed to produce a reliable seal would compress the PDMS and may have changed the chamber 
height. 
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A.2.3 Glass and acrylic 
A collaboration with Daniel McKeel produced a flow chamber design that consisted of side ports 
into reservoirs on either side of a channel that when filled, will produce a laminar flow across the 
channel (Figure 11).  This chamber was similar to that described by Chung et al to maximize the 
area of laminar flow over the test samples and minimize jetting.[181] The incorporation of the 
glass cover slip created a clear, thin window into the flow path.  
 
 
Figure 7.11: Longitudinal cross-section of the glass and acrylic chamber design. The red surfaces are acrylic, 
the light blue rectangle is a glass cover slip, and the yellow block is the material test sample.  Part of the 
acrylic block and cover slip area are transparent in order to show one of the inlet ports; the other port has 
been cut off but would exit towards the reader. 
 
Though the chamber was successful at producing laminar flow across the test material, 
several problems with this design excluded it from use.  The most serious problem was that the 
fluid gap through the plates was large, necessitating a very large volume of blood relative to the 
previous chamber designs.  This was a result of precision limitations with the milling equipment 
available.  The smallest gap height achieved was 0.1”, which is an order of magnitude larger than 
the PDMS channels.  In order to perfuse this chamber at the highest wall shear rates (1000 s-1) 
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for 5 minutes, it would require approximately 1.6 L; in contrast, a PDMS chamber with gap 
height 0.01” under the same conditions would require 16 mL.  
Another limitation with this design was the difficulty in controlling the glue that attaches 
the glass cover slip to the acrylic (Figure 12).  The edges of the glue were very uneven and 
allowed blood to stagnate between cracks.  This made the chamber a possible source of 
thrombosis and increased the error in the system.  Ultimately these problems led to abandoning 
the design. 
 
     
Figure 7.12: Blood perfusion studies with the acrylic chamber.  Left: blood leaking into imperfections in the 
glue between the acrylic chamber and the glass cover slip.  Right: a sample material being exposed to flowing 
blood in the acrylic chamber. 
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APPENDIX B 
CANDIDATE MATERIALS SELECTION AND PRELIMINARY TESTING 
B.1 MATERIALS AQUIRED FOR TESTING 
As discussed in Chapter 5, several materials were tested as alternatives to Ti6Al4V as the blood-
contacting surfaces in cardiovascular devices. Each material tested was FDA approved for 
medical implantation, and each material had physical properties amenable to use within a 
continuous flow VAD (similar to TiAl6V4) while providing advantages such as improved 
fabrication techniques (e.g. ability to be injection-molded). Prior to parallel plate flow chamber 
development (Appendix A), several preliminary tests of biocompatibility of these materials were 
performed. The results of these preliminary tests are presented below. 
1. TiAl6V4 (LaunchPoint Technologies Inc., Goleta, CA, USA) 
2. Alumina (Al2O3; LaunchPoint Technologies Inc. ) 
3. Zirconia Toughened Alumina (ZTA; CoorsTek, Inc., Golden, CO, USA) 
4. Yttria Tetragonal Zirconia Polycrystal (YTZP; CoorsTek) 
5. Magnesia partially stabilized Zirconia (DuraZ TM; CoorsTek) 
6. Polyetheretherketone (PEEK) 
7. 30% Carbon Fiber PEEK (CF-PEEK) 
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8. Implantable Grade Polyetherketoneketone (PEKK) 
9. Silicon Carbide (SiC; CoorsTek, Inc., Golden, CO, USA) 
10. Silinated methacryloyloxyethyl phosphorylcholine polymer – coated TiAl6V4 (SiMPC; 
generously provided by Dr. William Wagner’s Lab using established protocols [88])  
11. Poly(MPC)-co-methacryl acidpolymer coating on TiAl6V4 (PMA; generously provided by Dr. 
William Wagner’s Lab using established protocols [198])  
Unfortunately not all of the materials collected were able to be tested using the parallel 
plate flow chamber due to unforeseen autofluorescence at the wavelength necessary for 
visualization of quinacrine dihydrochloride – labelled platelets. The samples that autofluoresced 
were PEEK, CF-PEEK and PEKK. Additionally, the DuraZ samples were too short to fit the 
flow path of the parallel plate chambers and could not be included in the experiments. 
B.2 COMPARATIVE CLOTTING TIME ASSAY 
B.2.1 Introduction 
As stated earlier, a variety of materials may fulfill the mechanical and processing requirements to 
be employed in mechanical circulatory support devices as an alternative to the commonly 
utilized TiAl6V4. Novel materials or coatings may retain the attractive physical characteristics of 
TiAl6V4 while improving the biocompatibility of the blood contacting surface. In vitro 
biocompatibility testing of novel materials or coatings at the pre-clinical stage of device 
development allows for easier implementation and testing. Additionally, the ovine model is often 
chosen for adult and pediatric VAD evaluation and therefore ovine blood should be considered 
for use during in vitro biocompatibility testing. The following was a first-level evaluation of the 
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hemocompatibility of several alternative materials compared with TiAl6V4 using a standard 
blood clotting time assay with ovine and human blood. 
B.2.2 Methods 
Briefly, test materials were washed in Tergazyme ®for > 20 min, washed in Simple Green ® for 
>20 min, rinsed with DI wather 5 times and rinsed 3 times in physiological saline solution. Each 
material was placed into an empty 5 ml no-additive Vacutainer TM (BD) tube. Human or sheep 
blood was collected in sodium citrate tubes (1:10) following radial (human) or jugular (ovine) 
venipuncture; the first 3 ml was discarded to reduce activation of the coagulation system from 
the venipuncture. Fresh citrated human or sheep whole blood was added to each Vacutainer 
tubes (4 ml), re-calcified with 4 nM CaCl (final concentration), capped and placed on a 
hematology rocker at room temperature. An additional empty Vacutainer tube was included on 
the rocker as a negative control. The SiC material was not able to be tested as these samples did 
not fit within the Vacutainer tubes. The SiMPC and PMA samples were smaller than the other 
materials and were tested separately against a TiAl6V4 sample of the same size. Each material 
tested had similar surface roughness (~8 Ra) and blood volume to surface area ratio (0.90 ± 0.05 
cm²/mL for SiMPC, PMA, and the size-matched TiAl6V4; 1.4 ± 0.10 cm²/mL for all other 
samples). The time to clot was recorded in seconds, starting at the addition of the CaCl and 
stopping at near – complete coagulation of the blood by visual inspection. Each test was 
normalized by the clotting time of the negative control sample to reduce between – subject 
variability of blood collection; this was especially necessary for the sheep samples due to their 
excitability during blood collection. The normalized data was analyzed using a two – tailed t-test 
against TiAl6V4, with significance at p<0.05 
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B.2.3 Results and Discussion 
The PEEK and PEKK samples exhibited significantly longer clotting times than TiAl6V4 in both 
human and sheep blood (Figures 1 and 2); sheep blood also exhibited significantly longer 
clotting times for the CF-PEEK than TiAl6V4 (Figure 2). Though most of the ceramic samples 
produced longer clotting times than TiAl6V4, none of these differences were significant. 
Additionally, both SiMPC and PMA had longer clotting times than TiAl6V4 in ovine blood 
(Figure 3). 
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Figure 7.13: Clotting time results using re-calcified human blood and compared to TiAl6V4. 
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Figure 7.14: Blood clotting-time results using re-calcified sheep blood and compared to TiAl6V4. 
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Figure 7.15: Clotting-time results using re-calcified sheep blood and compared to uncoated Ti6Al4V. 
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The application of a standardized blood clotting time assay to alternative VAD blood 
contacting materials provided a first level analysis of the biocompatibility of these materials. 
While this method may not be as controlled as an experiment as the parallel plate flow studies, 
the combination of several different types of flow within the tubes (including both turbulent and 
stagnant areas) and a relatively high blood volume to surface area ratio provides a very 
challenging environment for the materials. Sheep and human blood produced similar results, 
with PEEK and PEKK exhibiting a significantly longer blood clotting time. The longer clotting 
times for PEEK and PEKK suggest a possible improved biocompatibility over TiAl6V4. 
Similarities between the sheep and human results provide encouragement that pre-clinical 
biocompatibility testing in sheep will yield relevant predictive information on the performance of 
cardiac devices in humans. 
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